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1. Introduction 
Insulin-like growth factors (IGFs) are, besides other mechanisms, controlled by growth 
hormone (GH) secretion and there are at least two different IGFs: IGF-1 and IGF-2. IGFs 
regulate various cellular processes e.g. survival, differentiation and proliferation (McMorris 
et al. 1986; McMorris & Dubois-Dalcq 1988; Mozell & McMorris 1991). 
Growth hormone, which induces IGF-1 secretion from the liver, is generated in the anterior 
pituitary and regulated by the hypothalamus via growth hormone releasing hormone 
(GHRH) and growth hormone inhibiting hormone (GHIH) (Jansson et al., 1985; Carlsson & 
Jansson 1990). IGFs in the brain are synthesised de novo or transported across the blood 
brain barrier (BBB) and seem to induce a variety of effects on the central nervous system 
(CNS). So far, the exact transport mechanisms of IGFs into the brain are not fully 
understood (Duffy, Pardridge, and Rosenfeld 1988). 
In the rodent brain, IGF-1 is mainly expressed in neuron-dense regions like the 
hippocampus, striatum, thalamus, hypothalamus and olfactory bulb (Rotwein et al. 1988; 
Bondy et al. 1990; Garcia-Segura et al. 1991). Accordingly, the insulin-like growth factor-1 
receptors (IGF-1Rs) are mainly found in the olfactory bulb, cerebellar cortex and granule cell 
layer of the dentate gyrus (Rotwein et al. 1988; Bondy et al. 1990; Bondy and Lee 1993; 
Werther et al. 1990). However, the function of IGF-1R mediated signals in the central 
nervous system (CNS) is still under investigation.  
After binding of IGF-1 to the IGF-1R, a signalling cascade is activated which leads to 
recruitment and subsequently phosphorylation of intracellular adaptor proteins, the so 
called insulin receptor substrates (IRS) (Jacobs et al. 1983; Rubin et al., 1983; Sun et al. 1991; 
Lavan et al. 1997; Lavan et al., 1997). Via these adaptor proteins, the MAP kinase (MAPK, 
mitogen activated protein kinase) cascade, as well as the phosphatidylinositide(PI)3-kinase 
signalling pathway, is turned on leading to protein kinase B (PKB/AKT) activation, which 
phosphorylates forkhead box O transcription factors (FoxO) causing their nuclear export 
(Stokoe et al. 1997; Alessi et al. 1996; Partridge & Bruning 2008). FoxO mediated 
transcription is involved in cell proliferation, differentiation and oxidative stress defence 
(Clark et al. 1993; Brunet et al. 1999; Dijkers et al. 2000; Dijkers, Medema, Pals et al. 2000; 
Medema et al. 2000) suggesting a function of FoxO during development and cellular stress 
response. 
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Recently, the function of the IGF-1R signalling pathway in neurons has been investigated 
using different model organisms like worms and flies as well as conventional and 
conditional mutagenesis in mice. These experiments revealed possible functions of IGF-1 
mediated signals in endocrine regulation, longevity, protein turnover and in the 
pathogenesis for ageing-associated diseases e.g. Alzheimer's Disease (AD). The current 
article discusses the mechanisms of regulation and the physiological as well as a possible 
pathophysiological role of IGF-1 mediated signals in the CNS.  
2. The GH/insulin-like growth factor system 
2.1 The somatotropic system  
Growth hormone (GH, somatotropin) is produced in the anterior pituitary by certain 
specified cells and regulated via the hypothalamus by the growth hormone releasing 
hormone (GHRH, somatoliberin), the growth hormone inhibiting hormone (GHIH, 
somatostatin), but also by suppression of the short loop negative feedback of GH itself 
(Jansson, Eden, and Isaksson 1985; Carlsson and Jansson 1990).  
The GH-producing cells of the anterior pituitary, also called somatotropes or somatotroph, 
form 30-40 % of the anterior pituitary (Gage et al. 1996). These cells require transcription 
factors of the POU-family (Mullis 2010) including the homeoproteins Pit-1 and Prop-1 
(prophet of Pit-1) for normal embryonic development and differentiation (Mullis 2005) as 
well as for GH expression. The expression of these transcription factors and therefore the 
differentiation of the somatotroph are controlled by GHRH producing neurons of the 
hypothalamus. Additionally, GH-release in the pituitary is inhibited by serum IGF-1 and 
enhanced by serum ghrelin (Wortley et al. 2005; Zigman et al. 2005) (Figure 1).  
In the periphery, GH mainly influences growth and development via IGF-1. IGF-1 and IGF-2 
can act endocrine, paracrine and autocrine (Cohick and Clemmons 1993; Stewart and 
Rotwein 1996; Mohan, Baylink, and Pettis 1996; Butler and LeRoith 2001). Additionally, 
there is a truncated form of IGF-1, Des(1-3)IGF-1, which lacks the tripeptide Gly-Pro-Glu at 
the N-terminus probably resulting from post-translational cleavage of IGF-1. Des(1-3)IGF-1 
is mainly expressed in brain and active in lower concentrations than un-truncated IGF-1 
(Ballard et al. 1996; Francis et al. 1988; Carlsson-Skwirut et al. 1989; Ogasawara et al. 1989). 
Studies on hypoxic-ischemic brain injuries in rats suggest that the tripeptide fragment has 
neuroprotective properties and influences neuronal activity (Guan et al. 1999).  
Circulating IGF-1 is mainly produced in the liver, but both IGF-1 and IGF-2 are expressed in 
many non-hepatic tissues (Cohick and Clemmons 1993; Stewart and Rotwein 1996; Butler 
and LeRoith 2001). The most important effects of IGFs are cell proliferation and 
differentiation, skeletal growth and mineralisation as well as the development and function 
of the reproductive organs and the central nervous system (CNS) (Duan and Xu 2005).  
GH is secreted pulsatile in rodents as well as in humans (Jansson, Eden, and Isaksson 1985; 
Frohman and Jansson 1986; Giustina and Veldhuis 1998) and follows a circadian pattern 
with one major peak after falling asleep. There is a sexual dimorphism in GH secretion, 
which is more dominant in rodents than in humans (Jansson, Eden, and Isaksson 1985; 
Tannenbaum and Martin 1976). In females, the GH secretory pattern seems to be less regular 
compared to males (Giustina and Veldhuis 1998), with higher basal interpulse GH levels, 
more frequent but lower amplitude pulses and a lower major nocturnal GH pulse (Jaffe et 
al. 1998; Jessup et al. 2003). Spontaneous and GHRH-stimulated GH secretion is suppressed 
more efficiently by IGF-1 in men than in women (Ohlsson et al. 2009) suggesting that also 
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sex steroids interfere with GH secretion (Veldhuis et al. 2008, 2009; Leung et al. 2004). Body 
growth is influenced more efficiently by GH if it is applicated in a pulsatile fashion than 
applied continuously (Jansson, Eden, and Isaksson 1985; Clark et al. 1985). This might be 
due to a higher induction of IGF-1 expression in growth plates and skeletal muscles by 
pulsatile GH, whereas continuous GH secretion stimulates liver IGF-1 expression and serum 
IGF-1 levels at least as well as a pulsatile GH release (Isgaard et al. 1988; Bick et al. 1992). 
Therefore, liver-derived IGF-1 is not essential for body growth itself. This effect might be 
achieved by locally produced IGF-1 and/or other factors (Ohlsson et al. 2009).  
 
 
  
Fig. 1. GH/ IGF-1 system 
Growth hormone releasing hormone (GHRH) and growth hormone inhibiting hormone 
(GHIH) are produced in neurons of the hypothalamus and transported via the hypothalmo-
pituitary portal vein system to the anterior pituitary where they regulate growth hormone 
(GH) secretion and expression. GH stimulates insulin-like growth factor-1 (IGF-1) 
production in the liver. In addition, free IGF-1 serum levels are regulated by binding to the 
insulin-like growth factor binding proteins (IGFBPs). A short negative feedback loop of GH, 
as well as a negative feedback mechanism of IGF-1 on the hypothalamus and possibly on 
the anterior pituitary, determines serum IGF-1 levels. 
Mouse models with tissue specific IGF-1 inactivation indicate that normal longitudinal bone 
growth is maintained by local bone-derived IGF-1 (Sjogren et al. 1999; Yakar et al. 1999). 
However, several other phenotypes, for example the one observed in the liver IGF-1 
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deficient (LID) mouse, suggest that locally derived IGF-1 cannot fully replace liver-derived 
IGF-1 function and vice versa.  
A lacking negative feedback of liver-derived IGF-1 on GH secretion leads to a compensatory 
increase in serum GH levels in mice (Yakar et al. 1999; Sjogren et al. 1999) and also in 
humans (Veldhuis et al. 2001). Hence, the phenotype of the LID mice might either arise 
directly or is mediated by the elevated GH-levels. LID mice show an increased expression of 
pituitary GHRH- and ghrelin-receptors indicating that at least some action of up-regulating 
GH secretion influences the pituitary (Ohlsson et al. 2009). However, the target sites of IGF-1 
for regulating GH-release remain unclear and might either be located in the hypothalamus 
and/ or the pituitary. Recently, a cell-specific knockout mouse in which the IGF-1 receptor 
(IGF-1R) was ablated from the somatotroph, the so called somatotroph IGF-1 receptor 
knockout (SIGFRKO) mouse, has been generated (Romero et al. 2010). The phenotype of the 
SIGFRKO mouse includes increased GH expression and secretion as well as increased serum 
IGF-1 levels (Romero et al. 2010). Feedback mechanisms in the hypothalamus resulted in 
decreased GHRH and increased GHIH mRNA levels (Romero et al. 2010). Furthermore, 
decreased growth hormone releasing hormone receptor (GHRH-R) expression was observed 
in the anterior pituitary (Romero et al. 2010). However, these changes were not able to 
reduce GH secretion in the SIGFRKO mouse indicating a role of IGF-1R signalling in the 
pituitary in addition to the hypothalamus in regulating GH secretion (Romero et al. 2010). 
IGF-1 influences glucose metabolism directly, e.g. by inducing insulin-like effects on 
glucose-uptake in tissues expressing IGF-1-receptors, but also by suppressing the GH-
release from the pituitary. GH is known to have diabetogenic effects (Yakar et al. 2004) by 
decreasing insulin-sensitivity in skeletal muscle, liver and fat. Consequently, LID mice show 
an impaired insulin-sensitivity. At the same time, those mice are protected against the 
increase in body fat mass that occurs in older age (Sjogren et al. 2001; Tang et al. 2005). This 
might be explained by elevated GH-levels in these mice (Ohlsson et al. 2009) as decreased 
GH secretion in both rodents and humans has been proposed to contribute to age-related 
obesity (Sonntag et al. 1980; Rudman et al. 1990). 
The inactivation of IGF-1 or its receptor during early development reduces brain size 
including a reduction of the granule cell layer in the dentate gyrus and the number of 
oligodendrocytes and myelinated axons (Beck et al. 1995; Holzenberger et al. 2001; Vicario-
Abejon et al. 2003) demonstrating the importance of IGF-1 signalling during brain 
development. LID mice show a milder phenotype with reduced exploratory activity 
(Svensson et al. 2005; Bohlooly et al. 2001), as well as impaired spatial learning and memory, 
suggesting that liver-derived IGF-1 enhances brain functions (Svensson et al. 2006). 
Circulating IGF-1 is essential for mediating exercise induced effects on the adult brain by 
promoting the numbers of newly generated neurons in the adult hippocampus, brain vessel 
growth, spatial learning and reducing anxiety (Trejo, Carro, and Torres-Aleman 2001; Trejo, 
Llorens-Martin, and Torres-Aleman 2008; Lopez-Lopez, LeRoith, and Torres-Aleman 2004). 
Additionally, liver-derived IGF-1 might enhance the clearance of brain amyloid-ǃ (Aǃ), 
whose aggregation is one of the hallmarks of AD (see 5.1).  
2.2 IGF-binding proteins 
Only a small amount of IGF-1 (~1 %) circulates “free” within the blood. The remaining 99 % 
are bound to IGF-binding proteins (IGFBPs). IGFBPs are a family of at least six proteins 
(IGFBP-1 to IGFBP-6), which bind IGF-1 with high affinities that are equal to or greater than 
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those of the IGF-1 receptor (Duan and Xu 2005). Additionally, there are several proteins with 
lower IGF-1 binding affinity, called IGFBP-related peptides (IGFBP-rPs), which have 
significant structural homologies with the amino(N)-terminal region of high-affinity IGFBPs 
(Rechler 1993; Kelley et al. 1996; Rajaram, Baylink, and Mohan 1997; Kim et al. 1997; Poretsky 
et al. 1999; Baxter 2000). So far, the functions of the IGFBP-rPs, also referred to as IGFBP- 7 to -
10, are not known (Mohan and Baylink 2002). Approximately 75-80 % of IGF is present as a 
150 kDa complex, which consists of IGF-1/IGF-2 plus IGFBP-3 (70-75 %) or IGFPB-5 (5-10 %) 
and an acid-labile subunit (ALS) (Baxter, Meka, and Firth 2002). ALS is mainly produced in the 
liver (Baxter 1988; Baxter and Martin 1989; Baxter, Martin, and Beniac 1989) and its gene 
disruption leads to a reduction of circulating IGFs of 80 % (Boisclair et al. 2001). The ternary 
complex of IGF-1 or -2/ IGFBP-3 or -5/ ALS extends the half-life of IGFs to 15-20 h, compared 
to a half-life of 20-30 min for free IGF-1 in circulation (Guler, Zapf, and Froesch 1987) 
suggesting a reservoir function of this complex, which cannot cross the vascular endothelial 
barrier (Rajaram, Baylink, and Mohan 1997; Baxter 2000). 20-25 % of the IGFs bind to IGFBP-1,-
2,-4 or -6 to form a complex, which is able to cross vascular endothelium (Baxter 2000; Rajaram, 
Baylink, and Mohan 1997). Thus, the endocrine actions of IGF-1 in serum are regulated by the 
IGFBPs determining how much IGF is bio-available to the local tissues.   
Furthermore, IGFBPs are located in the extracellular matrix or on the cell surface where they 
either inhibit (mainly IGFBP-4 and -6) or potentiate (mainly IGFBP-3 and -5) IGF-1 binding 
to its receptors (Rajaram, Baylink, and Mohan 1997; Mohan et al. 1995; Qin et al. 1998; Jones 
and Clemmons 1995; Firth and Baxter 2002; Rechler and Clemmons 1998). Functions of the 
IGFBPs might vary indicated by the inhibiting or potentiating effect of IGFBP-1, -2, -3 and -5 
on IGF-1 action depending on the experimental conditions (Yin, Xu, and Duan 2004). 
The actions of IGFBPs are, in turn, modulated by IGFBP proteases that are further 
dependent on activators and inhibitors (Mohan et al. 2002). Those IGFBP proteases are able 
to cleave IGFBPs, thereby reducing their affinity for IGF-1. Some of them are relatively 
specific for a given IGFBP. For example, pregnancy-associated plasma protein-A (PAPP-A), 
which is produced by a variety of cell types, cleaves specifically IGFBP-4 (Lawrence et al. 
1999; Byun et al. 2001; Conover et al. 2001), whereas complement C1s (Busby et al. 2000) and 
a disintigrin and metalloprotease-like (ADAM)-9 (Mohan et al. 2002) were identified to be 
relatively specific for IGFBP-5. Additionally, a number of other serum proteases were shown 
to be capable of cleaving IGFBPs, e.g. plasmin, cathepsin D and prostate specific antigen 
(Conover 1995; Fowlkes et al. 1995; Rajah et al. 1995; Rajaram, Baylink, and Mohan 1997; 
Maile and Holly 1999). Therefore, the binding affinity and hence the bio-availability of IGF-1 
is regulated via the degradation of IGFBPs through the IGFBP protease system.  
IGFBPs also have IGF independent functions, for example IGFBP-2 and -3 can induce direct 
cellular effects (Firth and Baxter 2002; Oh et al. 1993; Yamanaka et al. 1999; Schutt et al. 2004) 
and it has been shown that IGFBP-3 at least partially mediates these effects by binding to the 
cell surface, possibly to specific receptors (Mohseni-Zadeh and Binoux 1997; Rechler and 
Clemmons 1998). IGFBP-2, -3 and -5 contain sequences for nuclear localisation (Schutt et al. 
2004; Radulescu 1994; Schedlich et al. 1998; Hoeflich et al. 2004) and might as well influence 
gene expression.  
2.3 The insulin- and insulin-like growth factor-1 signalling pathway 
Insulin and IGF-1 receptors are receptor tyrosine kinases. Receptor tyrosine kinases contain 
a membrane-bound domain with tyrosine kinase activity which phosphorylates tyrosine-
residues of downstream signalling proteins. Typical members of the receptor tyrosine kinase 
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family are the epidermal growth factor receptor (EGFR), the nerve growth factor receptor 
(NGFR) and the insulin receptor (IR). The IR was discovered in 1974 and its tyrosine kinase 
was found in 1982 (Kasuga, Karlsson, and Kahn 1982; Kasuga et al. 1982). Later, in addition 
to the IR, the insulin-like growth factor-1 receptor (IGF-1R) was discovered as a tyrosine 
kinase activity containing receptor (Jacobs et al. 1983; Rubin, Shia, and Pilch 1983). 
The IR and IGF-1R are heterotetrameric structures. The different subunits are linked by 
disulfide bonds. The ǂ-subunits are exclusively localised extracellular (Van Obberghen et al. 
1981; Ullrich et al. 1986). The ǃ-subunits consist of a short extracellular part, a 
transmembrane domain and an intracellular part with ATP-binding motifs, 
autophosphorylation sites and tyrosine-specific protein kinase activity, which is activated 
after binding of insulin or IGF-1 to their receptors (Chou et al. 1987).  
The insulin receptor gene consists of 22 exons and 21 introns (Seino et al. 1989). Alternative 
splicing of exon 11, which codes for 12 amino acids, causes two different isoforms: A, which 
lacks the 12 amino acids, and B. This alternative splicing does not exist for the IGF-1 
receptor, because this receptor contains no equivalent to exon 11 of the IR. The A- and B-
isoforms both bind to insulin with similar affinity (McClain 1991). The A-isoform has a 
higher affinity to IGF-1 (Yamaguchi et al. 1991) and IGF-2 (Frasca et al. 1999) compared to 
the B-isoform. The A-isoform is expressed in hematopoietic cells, fetal tissue and the adult 
nervous system. The B-isoform of the IR is mainly present in liver, adipose tissue and 
muscle (Seino and Bell 1989; Moller et al. 1989; Goldstein and Kahn 1989; Mosthaf et al. 
1990). The selective binding of insulin or IGF-1 is also dependent on the assembly of the 
receptors (Pandini et al. 2002). The hybrid of IGF-1 receptor and the A-isoform of the IR 
binds IGF-1, IGF-2 and insulin with similar affinity. The hybrid of the IGF-1R and the B-
isoform of the IR only binds IGF-1 (Louvi, Accili, and Efstratiadis 1997).  
2.3.1 Insulin receptor substrates 
The binding of IGF-1 or IGF-2 to the IGF-1R causes a conformational change of the receptor, 
which induces autophosphorylation. This leads to the recruitment of insulin receptor 
substrates (IRS) to the autophosphorylated receptor tyrosine kinase, which in turn 
phosphorylates the tyrosine residues of the IRS proteins (Figure 2). The IRS protein family 
consists at least of four proteins, IRS-1 to IRS-4 (Sun et al. 1991; Lavan et al. 1997; Lavan, 
Lane, and Lienhard 1997).  
The IRS proteins show different expression patterns. IRS-1 and -2 are ubiquitously 
expressed, but IRS-3 is only present in rodent adipose tissue. IRS-4 mainly occurs in thymus, 
hypothalamus, kidney and heart. All IRS proteins share the same structural characteristics 
and have similar functions (Giovannone et al. 2000; Schubert et al. 2003).  
The four IRS family members contain an N-terminal pleckstrin homology (PH) domain, a 
phosphotyrosine-binding (PTB) domain and a C-terminal tail containing multiple tyrosine 
phosphorylation sites. The phosphotyrosine motifes of the IRS proteins are binding sites for 
Src homology(SH)2 domain-containing proteins (Yenush and White 1997). The PH domain 
binds to lipids and with high affinity to phosphoinositides (Fruman, Rameh, and Cantley 
1999). The PTB domain of IRS binds to phosphotyrosine residues of other proteins including 
the IR and IGF-1R. In more detail, the PTB domain binds to the phosphorylated NPXP motif 
at the juxtamembrane domain of the receptor after binding of insulin or IGF-1. Following 
binding to this motif, the IRS proteins are tyrosinephosphorylated (Cheatham and Kahn 
1995; White 2002).  
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Only IRS-2 contains a domain which binds to the phosphorylated kinase regulatory loop of 
the ǃ-subunit of the IR. This domain is called the KLRB domain (Sawka-Verhelle et al. 1997; 
Sawka-Verhelle et al. 1996). However, the physiological function of the KLRB domain of 
IRS-2 remains unclear. 
Insulin induces tyrosine and serine phosphorylation of IRS-1 (Gual, Le Marchand-Brustel, 
and Tanti 2005). These phosphorylations lead to specific regulation of downstream 
signalling. The phosphorylation of serine residues of IRS-1 contribute to positive or negative 
regulation of IRS-1 action (Weigert et al. 2005; Weigert et al. 2008). Important for this 
regulation are the particular phosphorylation sites (Herschkovitz et al. 2007) as well as the 
timing of phosphorylation (Weigert et al. 2005; Weigert et al. 2008). Currently, the serine 
phosphorylation sites with positive effect on IRS-1 action are regarded to be phosphorylated 
at first to support IRS-1 activity protecting from phosphorylation at residues with inhibitory 
effect (Weigert et al. 2005; Weigert et al. 2008; Gual, Le Marchand-Brustel, and Tanti 2005; 
Luo et al. 2007). In addition, serine phosphorylation with activating effect might prevent the 
association of IRS-1 with tyrosine phosphatases (Luo et al. 2005). The serine residues with 
inhibitory effect are located near the PTB domain. These residues are phosphorylated later 
than the residues with positive effect upon insulin stimulation or other signals. The 
phosphorylation of serine sites near the PTB domain causes disruption of the binding 
between IRS-1 and the IR followed by degradation of IRS-1. The phosphorylation of 
inhibitory serine residues in the C-terminus of IRS-1 disturb their interaction with the 
phosphatidylinositide (PI)3-kinase (Figure 2) (Gual, Le Marchand-Brustel, and Tanti 2005; 
Boura-Halfon and Zick 2009). Serine sites with inhibitory effect are phosphorylated by 
serine kinases like the mammalian target of rapamycin (mTor), PKCzeta and p70S6 (S6K) 
kinase (Boura-Halfon and Zick 2009; Herschkovitz et al. 2007; Gual et al. 2003). Insulin and 
IGF-1 resistance might be induced via kinases like c-Jun N-terminal kinase (JNK), 
mTor/S6K, inhibotory-κB kinase ǃ (IKKǃ), SIK-2 and extracellular signal regulated kinases 
(ERK) promoting the phosphorylation of the inhibitory sites of the IRS proteins (Boura-
Halfon and Zick 2009; Herschkovitz et al. 2007). The IRS-2 serine phosphorylation sites are 
still under investigation. It is known that JNK phosphorylates Thr348 of IRS-2 which is 
located near the PTB domain (Solinas et al. 2006) and might cause disruption of the binding 
between IRS-2 and the receptor. Furthermore, JNK phosphorylates Ser488 of IRS-2 
promoting the phosphorylation at Ser484 by glycogen synthase kinase (GSK)-3ǃ and thereby 
inhibiting the signalling pathway (Sharfi and Eldar-Finkelman 2008). 
2.3.2 PI3K signalling 
The mammalian phosphatidylinositide(PI)3-kinases are subdivided into three classes, class 
I-III. Class I is further divided into Ia and Ib (Vanhaesebroeck et al. 2005). These classes 
catalyse the phosphorylation of the 3´hydroxyl position of phosphatidyl-myo-inositol lipids. 
The PI3K of the insulin and IGF-1 signalling pathway belongs to the class Ia kinases 
(Fruman, Meyers, and Cantley 1998). These kinases display a heterodimeric structure 
containing a catalytic subunit of 110 kDa. This subunit is non-covalently associated with a 
50-, 55- or 85 kDa regulatory subunit. Following activation of the insulin receptor and IRS 
binding, the PI3K is recruited to the membrane via the p85 regulatory subunit. Other 
recruited factors are the growth factor receptor binding protein (GRB)-2 and the SH2-
Phosphatase(SHP)2 (Figure 2). 
The activated PI3K, in turn, phosphorylates phosphatidylinositide-diphosphate (PI4,5P) to 
produce phosphatidylinositide-triphosphate (PI3,4,5P). This event is reversible by PTEN (the 
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phosphatase and tensin homolog deleted on chromosome ten). The generation of PI3,4,5P 
causes activation of the downstream signalling proteins like phosphoinositide-dependent 
protein kinase (PDK) and protein kinase B (PKB, AKT). PDK is present in two isoforms, 
PDK-1 and PDK-2. PDK-1 phosphorylates AKT at Thr308, which partially activates AKT. To 
completely activate AKT, phosphorylation of Ser473 is necessary (Alessi et al. 1996; Lawlor 
and Alessi 2001; Stokoe et al. 1997). AKT is a serine/threonine kinase with a size of 57 kDa. 
It contains a PH domain and there are three isoformes, AKT-1, AKT-2 and AKT-3. These 
isoforms display a conserved domain structure: a kinase domain, a PH-domain at the N- as 
well as a regulatory subunit at the C-terminus (Hresko, Murata, and Mueckler 2003). AKT 
phosphorylates tuberin 2 (TSC-2). TSC-1 and -2 form a heterodimer with GTPase activity 
that inhibits the GTPase RHEB (RAS homolog enriched in brain). The phosphorylation via 
AKT causes the accumulation of the RHEB-GTP complex which activates mTOR (Astrinidis 
and Henske 2005; Hay and Sonenberg 2004). Furthermore, S6K is activated by 
phosphorylation of PDK-1 and mTOR (Figure 2). The regulation of protein synthesis via 
IGF-1 occurs through controlling the intrinsic activity and/or binding properties of specific 
translation initiation and elongation factors called eIFs and eEFs. mTOR phosphorylates 4E-
BP (4E binding protein). This causes the release of eIF4E (eukaryotic initiation factor 4E) to 
form an active complex, which promotes translation initiation and also activation of S6K. 
S6K phosphorylates the eEF2 (eukaryotic elongation factor 2) kinase which releases eEF2 
and initiates elongation (Figure 2) (Nojima et al. 2003; Oshiro et al. 2004). 
Other proteins, which are regulated via IR and IGF-1R signalling, are the glycogen synthase 
kinase(GSK)-3ǃ, a major tau kinase, and BAD (Bcl-2/Bcl-X-associated death promoter),  
a proapoptotic factor. These proteins are inactivated via the IR/IGF-1R signalling cascade 
(Song, Ouyang, and Bao 2005). BAD interacts with the apoptosis suppressors Bcl-2 and  
more intense with Bcl-XL (Yang et al. 1995). BAD directly binds to Bcl-XL with its BH3 
homology domain (Zha et al. 1997). This interaction is regulated by the phosphorylation 
state of BAD. Therefore, the IGF-1R signalling is a potent inhibitor of neuronal apoptosis 
(Schubert et al. 2003). 
2.3.3 Forkhead box O transcription factor 
AKT phosphorylates the Forkhead box O transcription factors (FoxOs). This induces the 
binding to 14-3-3 and nuclear exclusion of FoxOs and thereby inactivation of FoxO-
mediated transcription. FoxOs regulate transcription of genes, which are involved in 
apoptosis, metabolism, growth, ageing and development (Partridge and Bruning 2008). 
The mammalian FoxO protein family consists of 4 members: FoxO1, FoxO3a, FoxO4 and 
FoxO6. These transcription factors contain a conserved DNA binding domain, the 
forkhead domain (FKHR) (Clark et al. 1993). FoxO1 and FoxO3a are ubiquitously 
expressed, whereas FoxO6 is exclusively found in the brain, and FoxO4 has yet not been 
detected in the brain (Furuyama et al. 2000; Jacobs et al. 2003). The expression pattern of 
the different FoxOs in the adult mouse brain is distinct. FoxO1 is predominantly 
expressed in the striatum, dentate gyrus and ventral hippocampus and FoxO3a in the 
cortex, cerebellum and hippocampus. FoxO6 is expressed in amygdala, hippocampus and 
cingulite cortex (Hoekman et al. 2006). 
The FoxO transription factors are regulated by post-translational modifications. One major 
modification is the phosphorylation of the FoxOs. FoxO1 is phosphorylated by AKT at 
Thr24, Ser256 and Ser319 (Biggs et al. 1999; Brunet et al. 1999; Kops et al. 1999; Rena et al. 
1999; Tang et al. 1999). Phosphorylation triggers binding to 14-3-3 and subsequently 
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translocation out of the nucleus terminating FoxO mediated transcription (Figure 2) (Brunet 
et al. 1999). Additionally, FoxOs are phosphorylated by other kinases depending on the 
stimulus (Huang and Tindall 2007). Furthermore, FoxOs are regulated by ubiquitylation. 
Ubiquitylation is dependent on phosphorylation of Ser256 of FoxO1 via AKT (Huang et al. 
2005). FoxO1 and FoxO3a need to be polyubiquitylated for degradation. In contrast, FoxO4 
requires monoubiquitylation to be degraded (van der Horst et al. 2006). Another regulatory 
mechanism for FoxO transcription is acetylation. CBP and p300 with their associated 
proteins, for example CBP- and p300-associated factor (PCAF), display intrinsic histone 
acetyl-transferase activity. These proteins promote transcription via histone acetylation and 
they directly regulate transcription via acetylation of particular transcription factors (Li et al. 
2002). It has been shown that CBP acetylates FoxO transcription factors and inhibits their 
action (Daitoku et al. 2004). Silent information regulator 1 (SIRT1) is a nicotinamide adenine 
dinucleotide(NAD)-dependent histone deacetylase, which forms a complex with acetylated 
FoxOs upon stress stimuli and deacetylates the transcription factors (Brunet et al. 2004; 
Kitamura et al. 2005) to regulate FoxO mediated transcription. 
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Fig. 2. IR/IGF-R signalling 
The binding of Insulin or IGF-1 to the IR/IGF-1R causes autophosphorylation and activation 
of the receptor. Insulin receptor substrates (1-4) are recruited to the activated receptor and 
IRS phosphorylation results in activation of the MAP kinase (MAPK, mitogen activated 
protein kinase) and phosphatidylinositide(PI)3-kinase (PI3K) pathway. 
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3. IGF-1 signalling in the brain 
3.1 IGF-1’s transport across the blood brain barrier 
In the brain, present IGFs arise either by de novo synthesis or by transport from the blood 
into the brain. So far, the exact mechanisms of how IGFs cross the blood-brain barrier (BBB) 
are not fully understood. Early in vitro studies by Duffy and colleagues on isolated human 
brain capillaries showed that the affinity of IGF-2 to isolated human brain capillaries was 
approximately twofold higher than the affinity of IGF-1 binding and binding of both IGFs 
was nonsaturable over the range of 1 to 200 ng/ml IGF suggesting that there is a very 
efficient endocytosis mechanism (Duffy, Pardridge, and Rosenfeld 1988). Insulin displaced 
binding of IGF-1 (50% inhibited by 2 µg/ml Insulin) and IGF-2 (50% inhibited by 0,5 µg/ml 
Insulin). Furthermore, binding was largely inhibited by adding human serum, which was 
assumed to be due to the presence of IGFBPs (Duffy, Pardridge, and Rosenfeld 1988). 
Subsequent studies suggested that there might be a high capacity transport system across 
the BBB, which is influenced by the IGFBPs (Pan and Kastin 2000). Tores-Aleman and co-
workers found that via the choroid plexus epithelium, circulating IGF-1 is transported into 
the CSF through a mechanism involving the multicargo protein tranporter low-density 
lipoprotein receptor related protein 2 (LRP2), and concluded that increasing levels of IGF-1 
in the CSF, as a result of increasing IGF-1 levels in the serum, might be explained via this 
transport mechanism (Carro et al. 2000; Carro et al. 2005). LRP1, another membrane cargo-
transporter, was suggested as targeting platform for the circulating IGF-1/IGFBP-3/ALS-
complex (Nishijima et al. 2010). LRP1 is abundantly expressed in brain endothelium and 
seems to be a cellular receptor for IGFBP-3 (Huang et al. 2003). Recently, it has been 
demonstrated that neuronal activity increases the permeability of the BBB for IGF-1 through 
neurovascular coupling (Nishijima et al. 2010). Therefore, serum IGF-1 might influence brain 
processes like synaptic plasticity and cognition. Furthermore, neurovascular coupling was 
proposed to locally change cerebral blood flow leading to activation of matrix 
metalloprotease 9 (MMP9) through diverse mediators (arachdonic acid derivates, ATP, etc.). 
MMP9 is an IGFBP-3 cleaving protease, which is released in response to neuronal activity 
(Michaluk and Kaczmarek 2007) and might link neuronal activation to the transport of 
serum IGF-1 via a LRP1 depending mechanism across the BBB (Nishijima et al. 2010). 
Hence, neurovascular coupling might result in neurotrophic coupling explaining the 
neuroprotective effects of physical as well as mental exercise and active social life on brain 
function (Carro et al. 2000; Fratiglioni, Paillard-Borg, and Winblad 2004).  
3.2 Brain IGF receptors 
IGF-1 and to less extend IGF-2 bind and therefore activate the type 1 IGF-receptor (IGF-1R) 
(Rubin and Baserga 1995; White and Kahn 1994; LeRoith 2000). Several IGF-1R subtypes 
have been reported, for example the hybrid IGF-1Rs, which are hybrid dimers of the insulin-
receptor (IR) and the IGF-1R (see 2.3) binding insulin as well as IGFs with similar affinity 
(Soos and Siddle 1989; Soos et al. 1990; Siddle et al. 1994; Moxham, Duronio, and Jacobs 
1989; Pandini et al. 2002). The physiological significance of these receptor subtypes is still 
unclear (Russo et al. 2005). 
Additionally, there is a type 2 IGF-receptor (IGF-2R) with a short cytoplasmic domain 
lacking a tyrosine kinase harbouring a higher affinity for IGF-2 than the IGF-1R (Sakano et 
al. 1991; Oh et al. 1991; Dore, Kar, and Quirion 1997; Braulke 1999; Kiess et al. 1994). This 
IGF-2R is a cation-independent mannose-6 phosphate (M6P) receptor binding not only IGF-
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2 but M6P-containing ligands. This receptor functions in the mediation of endocytosis and 
lysosomal enzyme trafficking and regulation of apoptotic/ mitogenic effects (Morgan et al. 
1987; von Figura and Hasilik 1986; Ghahary et al. 2000). Recent studies have demonstrated 
that IGF-2 influences memory enhancement via the IGF-2R suggesting that the IGF-2R 
might transmit some intracellular signalling (Chen et al. 2011). 
3.3 IGF receptor expression in the brain 
IGF-1R mRNA is widely expressed in the developing CNS and persists at high levels in the 
mature brain especially in neuron-rich regions such as the olfactory bulb, the granule cell 
layer of the dentate gyrus and cerebellar cortex (Rotwein et al. 1988; Bondy et al. 1990; 
Bondy and Lee 1993; Werther et al. 1990). Glia cells have a lower IGF-1R expression than 
neurons and therefore regions mainly containing those cells, like white matter zones, show 
low IGF-1R mRNA levels (Bondy and Lee 1993). Some neurons, which are still in the process 
of developing, express increasing IGF-1R mRNA levels postnatal until they have reached 
maturity, for example Purkinje cells (Bondy et al. 1992). In the adult brain, high expression 
levels of IGF-1R mRNA are also found in the choroid plexus, meninges and vascular sheaths 
(Bondy et al. 1992; Bohannon et al. 1988; Werther et al. 1989; Matsuo et al. 1989; Marks, 
Porte, and Baskin 1991). 
The IGF-2R is abundantly expressed in the CNS, especially in the pyramidal cell layers of 
the hippocampus, the granule cell layer of the dentate gyrus, olfactory bulbus, choroid 
plexus as well as in the microvasculature, retina, pituitary, brainstem and spinal cord 
(Hawkes and Kar 2004; Couce, Weatherington, and McGinty 1992; Wilczak et al. 2000; 
Valentino, Ocrant, and Rosenfeld 1990).  
In addition to the IGF-1R and the IGF-2R, IR and IGF-1R hybrids are expressed in the brain, 
through which IGFs and insulin induce intracellular signalling. IRs are mainly expressed in 
regions that are linked to olfaction, appetite and autonomic functions, such as the olfactory 
bulb, limbic system and hypothalamus (Werther et al. 1987; Unger, Livingston, and Moss 
1991) and seem to play a key-role in controlling feeding, body weight and reproduction 
(Bruning et al. 2000). Furthermore, IR expression is also present in remarkable concentration 
in the choroid plexus, circumventricular organs and brain microvessels (van Houten and 
Posner 1979, 1981; Werther et al. 1987) suggesting the IRs might contribute to the transport 
of insulin and possibly IGF-1 across the BBB.  
4. IGF-1 action in the developing brain 
4.1 Brain growth and myelination 
Different mouse models indicated the essential actions of IGF-1 signalling for normal brain 
development. Homozygous IGF-1 knockout mice (IGF-1-/-), homozygous IGF-2 knockout 
mice (IGF-2-/-) as well as doubly deficient mutants are viable but have small brains (Beck et 
al. 1995; Liu et al. 1993). The majority of homozygous IGF-1-/- mice die perinatally and those 
which survive (< 5 %) demonstrate severe growth retardation with reduction in brain 
weight of 38 % distributed evenly over all major brain areas (Beck et al. 1995). However, 
certain cell-types and brain-regions were especially affected by the IGF-1 gene disruption 
such as white matter, striatum and hippocampus (Beck et al. 1995). The reduction of white 
matter was due to a net loss of axons and an additional shift from myelinated to 
unmyelintated fibres indicating the role of IGF-1 in axonal growth and/or maturation and 
its effect on the amount of oligodendrocytes and axon-myelination (Beck et al. 1995). These 
findings are in line with many in vitro studies, which demonstrated a stimulating effect of 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
220 
IGF-1 on oligodendrocyte survival, development and proliferation (McMorris et al. 1986; 
McMorris and Dubois-Dalcq 1988; Mozell and McMorris 1991). In addition, formation of 
hippocampal granule cells and striatal parvalbumin-containing neurons was reduced in 
IGF-1-/- mice and therefore seems to require IGF-1 (Beck et al. 1995). Most dentate granule 
neurons as well as the myelination of axons are generated during postnatal development 
(Altman and Bayer 1990, 1990; Morell et al. 1972; Matthieu, Widmer, and Herschkowitz 
1973) suggesting that IGF-1 plays a more important role during late embryonic and 
postnatal development. Intrauterine development was analysed in detail in single and 
combined homozygous knockout mice for IGF-1 and IGF-2 suggesting that before E13.5 the 
IGF-1R exclusively mediates IGF-2 actions and later, with increasing IGF-1 expression, the 
IGF-1R interacts with both IGFs (Baker et al. 1993). IGF-2 was found to be upregultaed in 
IGF-1-/- mice suggesting that IGF-2 may partially compensate for the loss of IGF-1 
expression and function (Ye et al. 2002).  
Homozygous IGF-1R knockout mice (IGF-1R-/-) die at birth and have smaller brains (Liu et 
al. 1993). A similar growth retardation of the CNS was observed in transgenic mice 
overexpressing human IGFBP-1 (hIGFBP-1) suggesting reduced IGF-1 action via IGF-1Rs 
(D'Ercole et al. 1994). Conversely, transgenic mice overexpressing human IGF-1 (hIGF-1) 
show increased brain growth and myelination (Carson et al. 1993; Ye, Carson, and D'Ercole 
1995). In both mouse models, the transgenic hIGFBP-1 and hIGF-1 mouse, the cerebral 
cortex, hippocampus and diencephalon were the most affected brain regions (Ye, Carson, 
and D'Ercole 1995). Myelination was increased in hIGF-1 and reduced in hIGFBP-1 
transgenic mice as well as the number of oligodendrocytes and the expression of myelin-
specific proteins, respectively (Ye, Carson, and D'Ercole 1995). During development, the 
increase of myelin protein expression in the cerebral cortex of hIGF-1 transgenic mice 
correlates with the hIGF-1 transgene mRNA levels (Ye, Carson, and D'Ercole 1995). In 
conclusion, IGF-1 plays a crucial role in regulating neuronal growth and differentiation 
(Werther et al. 1998), but also enhances oligodendrocyte survival and myelination (Beck et 
al. 1995). 
Several studies suggested that transcriptional programs control the development of axons or 
dendrites including their growth and branching (Jan and Jan 2003; Goldberg 2004; Polleux, 
Ince-Dunn, and Ghosh 2007). Recently, the role of FoxO-transcription factors, major 
downstream-targets of IIS (Insulin/IGF-1 signalling pathway), within the developing brain 
and their action of conducting IGF-1 signalling started to become clearer. FoxO proteins 
were found to be key-regulators of neuronal polarity in the mammalian brain and to trigger 
differentiation from immature neurons to post-mitotic neurons with specified axon- and 
dendrite-formations (de la Torre-Ubieta et al. 2010). In addition, protein kinase Pak1 was 
identified as direct target of FoxO-transcription factors linking FoxO-dependent 
transcription in the nucleus to an enzyme that promotes axonal polarity by controlling actin 
and microtubule dynamics (Edwards et al. 1999; Wittmann, Bokoch, and Waterman-Storer 
2004) as well as dendritic spine morphogenesis and synapse differentiation (Hayashi et al. 
2004; Hayashi et al. 2007; Nikolic 2008). Apart from Pak1, FoxO knockdown neurons 
demonstrated a number of downregulated polarity genes, such as Par6, R-Ras, APC and 
CRMP2 (de la Torre-Ubieta et al. 2010). Additionally, FoxO3a was shown to regulate 
homeostasis of neuronal stem cells (NSCs) both in vitro and in vivo by controlling a set of 
genes that determines cell cycle re-entry and optimal oxygen and glucose metabolism 
(Renault et al. 2009). However, the effect of FoxO3a deficiency in NSCs only became 
apparent in adult animals, as NSCs were shown to influence learning, memory and mood 
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(Zhang et al. 2008). Therefore, NSC homeostasis regulated by FoxO3a might influence the 
decline of cognitive function and possibly the onset of neurodegenerative diseases (de la 
Torre-Ubieta et al. 2010).  
4.2 Neuroendocrine regulation 
Embryonic brain IGF-1R and therefore the action of the IGF-1 pathway in the developing 
brain was found to play a crucial role in determining somatotrophic plasticity and hence 
postnatal GH and IGF-1 signalling. These observations were made in a brain specific IGF-1R 
knockout mouse model (bIGF-1RKO-/-; bIGF-1RKO+/-) by the group of Holzenberger 
(Kappeler et al. 2008). Whereas homozygous mutants (bIGF-1RKO-/-) showed severe growth 
retardation and were infertile, heterozygous mutants (bIGF-1RKO+/-) were healthy and had 
an increased mean lifespan compared to controls (Kappeler et al. 2008). In bIGF-1RKO+/- 
mutants, serum IGF-1 and GH were lowered and pituitaries, like most other organs, were 
smaller compared to controls (Kappeler et al. 2008). As IGF-1Rs are only diminished in the 
brain but not in the anterior pituitary in this mouse model, the observed phenotype was 
proposed to result from alterations in GH-regulatory neurons of the hypothalamus. 
Hypothalamic GHRH expression was found to be significantly lower, as well as the Pit-1 
mRNA levels. bIGF-1RKO+/- mice had preserved gonado- and thyrotropic functions but 
were growth retarded with a body length 5 % shorter than controls and a body weight of 
about 90% of controls at the age of 90 days (Kappeler et al. 2008). Interestingly, weight gain 
with age was slightly higher in adult bIGF-1RKO+/- mice than in controls, and female 
mutants finally reached the same body weight than controls (Kappeler et al. 2008). The gain 
of weight was most probably due to an enlargement of subcutaneous adipose tissue (AT), as 
there was less or no increase in visceral AT (Kappeler et al. 2008). In line with GH-deficient 
mouse models (Berryman et al. 2004; Berryman et al. 2006), the bIGF-1RKO+/- mice showed 
impaired glucose homeostasis and fat metabolism. Heterozygous inactivation of IGF-1R had 
no detectable effects on behaviour or other brain functions apart from the somatotrophic 
deficit. Compared to control littermates, bIGF-1RKO+/- mice had a significantly longer mean 
lifespan. However maximum lifespan was unchanged probably due to increased late-life 
mortality caused by hyperglycemia and dyslipidemia (Kappeler et al. 2008). Early dietary 
restriction showed a similar neuroendocrine response as the brain specific IGF-1R knockout 
(Kappeler et al. 2008), indicating a connection between nutrition, somatotrophic hormones, 
growth and their determination of lifespan. 
Similar observations, in which morbidity in later life was determined during prenatal 
development, were made in humans. Long-term studies have been conducted on the Dutch 
famine birth cohort as well as on the Chinese famine cohort. Babies exposed in utero to 
calory restriction in late or mid gestation were growth retarded and showed impaired 
glucose tolerance in later life (Ravelli et al. 1998; Painter, Roseboom, and Bleker 2005). 
However, babies exposed in early gestation were not smaller than controls but 
demonstrated the most striking consequences of in utero undernutrition, namely a three-
fold increase in coronary heart disease, hyper-/dyslipidemia and more frequent obesity 
(Painter, Roseboom, and Bleker 2005; Ravelli et al. 1999; Roseboom, van der Meulen, 
Osmond, Barker, Ravelli, Schroeder-Tanka et al. 2000; Roseboom, van der Meulen, Osmond, 
Barker, Ravelli, and Bleker 2000). Interestingly, mortality rates at older (50+) ages are 
significantly higher in the exposed group, and residual life expectancy at age of 50 was 
reduced by approximately 3 years (Lindeboom, Portrait, and van den Berg 2010), which is in 
line with the increased late-life mortality observed in the bIGF-1R+/- mice. In the cohort of 
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the Chinese famine, fetal and infant exposure to undernutrition also resulted in increased 
risk for metabolic syndrome (Li et al. 2010; Li et al. 2011; Yang et al. 2008; Luo et al. 2006).  
In summary, IGF-1 signalling during early development is defined by the number of brain 
IGF-1Rs or their sensitivity and determines endocrine as well as metabolic function in later 
life possibly playing a key-role in pathogenesis of age-associated diseases. 
 
IGF-1 function in the developing 
brain 
IGF-1 function in the adult brain 
 growth and differentiation 
                of neurons 
 neuronal polarity and 
                synapse formation 
 growth of 
                oligodendrocytes 
 enhancement of myelination 
 neuroendocrine regulation of 
metabolism 
 preservation of neuronal 
plasticity, for example in the 
olfactory bulb 
 brain vessel growth 
 spatial learning and other 
cognitive functions 
 neuroprotecetive in ischemic or 
traumatic injuries and several 
neurological disorders 
 reduced signalling extends 
lifespan 
Table 1. Function of IGF-1 in the brain 
5. IGF-1 in Alzheimer's disease 
Alzheimer's disease (AD) is a chronic and progressiv neurodegenerative disease and the 
most common form of dementia leading to the loss of cognitive abilities and finally to death 
(Citron 2002; Cole et al. 2007). 
AD was first described by Alois Alzheimer, a German physician, in 1906 (Alzheimer et al. 
1995). The disease is characterised by ǃ-amyloid accumulation, formation of extracellular 
amyloid plaques as well as neurofibrillary tangles. The ǃ-amyloid plaques mainly contain 
aggregated amyloid-ǃ (Aǃ) peptides (Masters et al. 1985). In contrast, the main components 
of neurofibrillary tangles are hyperphosphorylated and aggregated tau proteins (Ross et al., 
2005). The aggregation of Aǃ is thought to be the molecular basis of neurodegenration in AD 
(Masters et al. 1985). 
5.1 Tau 
The tau proteins consist of a N-terminal projection domain, a short tail sequence and a C-
terminal domain with microtubule-binding (MTB) repeats. Six isoforms of tau are known in 
the human brain. These isoforms emerge from alternative splicing of exons 2, 3 and 10. Exon 2 
and 3 encode N-terminal parts of tau and exon 10 codes for an additional MTB repeat. Thus, 
tau can present three or four MTB repeats (Ballatore, Lee, and Trojanowski 2007; Goedert and 
Spillantini 2006). Tau is predominantly located in the axons of neurons (Hirokawa et al. 1996) 
and is to less extend found in dendrites (Ittner et al. 2010). The function of tau is yet not 
completely understood, but it might influence the stabilisation of microtubules and regulation 
of axonal transport (Gotz, Ittner, and Kins 2006). Tau is phosporylated at several sites via 
kinases like glycogen synthase kinase 3 (GSK-3ǃ), cyclin-dependent kinase 5 (Cdk5), c-Jun N-
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terminal kinase (JNK) and ERK1/2 (Robertson et al. 1993; Hanger et al. 1992; Flaherty et al. 
2000; Cho and Johnson 2004; Stoothoff and Johnson 2005). Abnormal high phosphorylation is 
called "hyperphosphorylation". Hyperphosphorylated tau proteins form so called paired 
helical filaments, which are characteristic for AD. The degradation of tau is inhibited by 
phosphorylation at the caspase cleavage sites. It has been shown that the mutation of Ser422, 
which causes a stable phosphorylation at this site, prevents caspase cleavage (Guillozet-
Bongaarts et al. 2006). GSK-3ǃ is one of the major tau kinases and is inactivated upon 
phosphorylation of Akt at Ser9 connecting insulin and IGF-1 signalling to tau 
phosphorylation. The major tau phosphatase in human brain is PP2A (Sontag et al. 1996), 
which is as well regulated via the IR/IGF-1R pathway suggesting that IR/IGF-1R signalling 
maintains an equilibrium of phosphorylation and dephosphorylation of tau (Liu et al. 2008; 
Millward, Zolnierowicz, and Hemmings 1999). 
5.2 Amyloid-β 
Aǃ is generated by proteolytic cleavage of the amyloid precursor protein (APP), a type-1 
integral membrane protein. APP was first described and cloned in 1987 (Kang et al. 1987; 
Tanzi et al. 1987; Goldgaber et al. 1987; Robakis et al. 1987). The APP gene is located on 
chromosome 21. Hence, patients with trisomy 21 show a higher risk to develop Alzheimer´s 
disease, because of the additional APP allele. Accordingly, the duplication of the isolated 
APP gene causes cerebral amyloid angiopathy and amyloidosis suggesting that increased 
APP expression itself is sufficient to cause Alzheimer-like pathology (Rovelet-Lecrux et al. 
2006; Sleegers et al. 2006). Another risk factor for AD are mutations of the APP gene (Vassar 
2004; Bertram and Tanzi 2005). APP contains a N-terminal extracellular domain and a 
shorter C-terminal cytoplasmic domain. Alternative splicing of the APP gene results in 
different isoforms of APP which are distinguishable by length. APP with 751 and 770 
(APP751 and APP770) amino acids mainly occur in non-neuronal tissue. APP695 is mainly 
localised in neurons (Kang and Muller-Hill 1990). The function of APP and the APP-like 
proteins (APLP) is not clear yet. These proteins are possibly involved in cell adhesion, 
apoptosis and axonal transport.  
The ǃ-secretase BACE1 (ǃ-site APP-cleaving enzyme) plays an essential role in the 
production of Aǃ. It cleaves APP at Asp+1 at the N-terminus. The resulting fragments are 
called APPsǃ and the C-terminal fragment C99. Upon cleavage of C99 by the Ǆ-secretase, a 
complex formed by presenilin, nicastrin, Aph-1 and Pen-2, Aǃ peptides (4 kDa) and the APP 
intracellular domain (AICD) with a size of 6 kDa are generated. Aǃ-peptides mainly occur in 
two variants: Aǃ40 which ends at residue 40 and Aǃ42 ending at residue 42 after cleavage. 
Predominantly, the Aǃ42 is prone to aggregate and forms toxic oligomers. Furthermore, 
APP is cleaved by the ǂ-secretases ADAM10 (a disintegrin and metalloproteinase-like 10) or 
TACE (tumour necrosis factor-alpha convertase). This results in the C-terminal fragment 
C83 and APPsǂ. The cleavage of APP by ǂ- or ǃ-secretase is dependent on the competition 
between both enzymes. In case the ǃ-secretase cleavage of APP increases, ǂ-secretase 
processing decreases and vice versa (Vassar et al. 1999; Skovronsky et al. 2000) (Figure 3). 
In a healthy brain, there is more production of Aǃ40 (~90 %) than there is of Aǃ42 (~5-10 %) 
(Walsh and Selkoe 2007). The accumulation of Aǃ42 is an important step in the formation of 
amyloid plaques (Iwatsubo et al. 1994). The Aǃ42:Aǃ40 ratio is a diagnostic tool for APP 
processing and development of AD (Haass and Selkoe 2007). 
In addition to age-associated Aǃ42 accumulation, mutations in presenilin 1, presenilin 2 and 
the APP gene lead to familiar early-onset AD (Tabaton and Tamagno 2007; Sherrington et al. 
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1996; Tanzi et al. 1992; Schellenberg et al. 1992; Van Broeckhoven et al. 1992; St George-
Hyslop et al. 1992; Rogaev et al. 1995).  
The toxic effect of Aǃ is not fully understood yet, but might be induced via generation of ion 
channels, membrane disruption, oxidative stress, induction of apoptosis and inflammation 
(Hardy and Selkoe 2002; Nakagawa et al. 2000; Soto 2003; Roberson and Mucke 2006). The 
Aǃ aggregation process produces different intermediates. Aǃ monomers are soluble and 
amphipathic with an ǂ-helical conformation and kink regions in water-alcohol mixture 
(Coles et al. 1998; Crescenzi et al. 2002). Aǃ40 displays a random coil structure in aqueous 
solution (Zhang et al. 2000) and Aǃ42 shows ǃ-sheet structure at physiological conditions 
(Barrow and Zagorski 1991). Aǃ dimers are located intracellular in vivo and show a 
hydrophobic core (Roher et al. 1996). Small Aǃ oligomers are highly cytotoxic compared to 
mature Aǃ fibrils (Dahlgren et al. 2002; McLean et al. 1999; Cleary et al. 2005; Lesne et al. 
2006). The so called Aǃ-derived diffusible ligands (ADDLs) show no fibrillar structure and 
are neurotoxic in a size of about 17 to 42 kDa (Chromy et al. 2003; Klein, Stine, and Teplow 
2004; Lambert et al. 1998). The levels of ADDLs are linked to cognitive impairments in AD 
(Georganopoulou et al. 2005). Aǃ protofibrils are the precursors of Aǃ fibrils. These 
protofibrils are present as rod-like and flexible structures. The dyes Congo red and 
thioflavin T bind to the core of the protofibrils, which indicates a high level of ǃ-sheets (Harper 
et al. 1999; Arimon et al. 2005; Harper et al. 1997; Kheterpal et al. 2003; Walsh et al. 1997; 
Williams et al. 2005). Aǃ fibrils are insoluble, thermodynamically stable aggregates containing 
repeats of ǃ-sheets (Ross and Poirier 2005). They also bind Congo red and thioflavin T (Klunk, 
Jacob, and Mason 1999; LeVine 1999). The amyloid plaques are extracellular aggregates of 
insoluble Aǃ fibrils (Muller-Hill and Beyreuther 1989). These plaques are surrounded by 
activated microglia, astrocytes and dystrophic dendrites (Selkoe 2004).  
Different clinical studies revealed an association of AD and type 2 diabetes (Janson et al. 
2004; Ott et al. 1999; Stewart and Liolitsa 1999). A connection of glucose intolerance, 
impairment of insulin secretion and the risk to develop AD was recently discovered (Ott et 
al. 1996; Luchsinger et al. 2004; Ronnemaa et al. 2008). Furthermore, AD patients develop 
more frequently impaired glucose tolerance and type 2 diabetes (Janson et al. 2004) 
indicating that IR/IGF-1R signalling might influence AD pathogenesis. 
 
 
Fig. 3. Processing of amyloid precursor protein (APP). 
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APP might be cleaved via the ǂ-, ǃ- or Ǆ-secretase. ǂ-secretase cleavage generates a 
membrane bound C83 fragment and sAPPǂ. In case C83 is proteolytically cleaved by the Ǆ-
secretase the P3 fragment occurs. ǃ-secreatse processing produces the fragments sAPPǃ and 
C99. In case of a simultaneous or subsequent cleavage via ǃ- and Ǆ- secretase the Aǃ40 or 
Aǃ42 peptides are released. 
5.3 IR, IGF-1R signalling and Alzheimer’s disease 
The IR and IGF-1R signalling pathway is disturbed in the central nervous system (CNS) of 
AD patients (Frolich et al. 1998; Frolich et al. 1999; Moloney et al. 2010). Analysis of the 
mRNA level of insulin and the IR showed a decrease of about 80% in AD patients. 
Additionally, the expression of the IGF-1R was reduced in AD brains compared to controls 
(Moloney et al. 2010; Rivera et al. 2005). In contrast, the IGF-1 serum levels of AD patients 
are increased indicating IGF-1 resistance in AD (Rivera et al. 2005; Vardy et al. 2007). 
Furthermore, IRS-1 and -2 expression is reduced in AD brains and phosphorylation of IRS-1 
at Ser312 and Ser616 is increased, which decreases IRS-1 action characterising AD as "brain 
type" diabetes (Pilcher 2006). Thus, brains of AD patients are insulin and IGF-1 resistant. 
Whether these changes are cause or consequence of neurodegeneration is a matter of debate. 
IGF-1 knockout mice display increase of tau phosphorylation at Ser396 and Ser202 while the 
tau protein level was not influenced (Cheng et al. 2005). In NIRKO mice, the brain-specific 
IR knockout mice, tau was hyperphosphorylated at Thr231 (Schubert et al. 2004), whereas 
IRS-2 knockout mice showed hyperphosphorylation at Ser202 (Schubert et al. 2003). The 
different phosphorylation patterns of tau in different insulin and IGF-1 resistant mouse 
models indicate that additional factors may play a role for tau phosphorylation in these 
models (Freude et al. 2009).  
Tg2576 mice express the Swedish mutation of APP (APPsw) and are an established mouse 
model for analysing amyloid pathology (Vassar et al. 1999; De Strooper 2003; Harada et  
al. 2006). IRS-2 (IRS-2-/-) or neuron specific IGF-1R knockout (nIGF-1R-/-) in Tg2576 mice 
protects these mice from premature death and decreases Aǃ-accumulation (Freude et 
al. 2009). 
BACE-1 and Presenilin-1/-2, which cleave APP and generate neurotoxic Aǃ42, are possible 
targets for AD treatment since ǃ-secretase cleavage is the rate limiting step of Aǃ generation. 
During ageing, the expression of the neurotrophin receptor tyrosine kinase receptor A 
(TrkA) and the p75 neurotrophin receptor (p75NTR) changes considerably. Whereas TrkA 
receptor expression decreases, the p75 neurotrophin receptor increases with age. Human 
neuroblastoma cells SHSY5Y and primary cultured neurons showed a switch from TrkA to 
p75NTR expression after treatment with IGF-1 (Costantini, Scrable, and Puglielli 2006). This 
increases BACE-1 activity via hydrolysis of sphingomyelin and release of ceramide 
stabilising BACE-1 (Puglielli 2008; Puglielli et al. 2003). It has been shown that embryonic 
hippocampal neurons treated with Aǃ42 as ligand of p75NTR cause cell death. Neurons, 
which are deficient in p75NTR and also treated with Aǃ42, show less cell death. This may 
represent the molecular mechanism linking IR and IGF-1R signalling pathway to ageing and 
neurodegeneration (Sotthibundhu et al. 2008). 
In Caenorhabditis elegans the knockdown of DAF-2, the orthologue of mammalian IR and 
IGF-1R, reduces Aǃ42 toxicity (Cohen et al. 2006). This reduced Aǃ42 toxicity results from 
the activity of the downstream transcription factors DAF-16, the orthologue of 
mammalian FoxO1 and 3a as well as heat shock transcription factor-1 (HSF-1) (Hsu, 
Murphy, and Kenyon 2003; Birkenkamp and Coffer 2003; Cohen et al. 2006). The 
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detoxification of Aǃ42 by decreased DAF-2 signalling involves two possible mechanisms. 
First, HSF-1 regulates disaggregation of toxic oligomers followed by degradation of the 
resulting fragments. Second, DAF-16 regulates the formation of aggregates with high 
molecular weight and low toxicity, which are built from aggregates with low molecular 
weight but high toxicity (Aǃ hyperaggregation) (Cohen et al. 2006). Recently, Aǃ 
hyperaggregation has been identified as a mechanism of Aǃ detoxification in an IGF-1 
resistant mouse model of AD (Cohen et al. 2009). 
Several ways of Aǃ clearance from the brain have been discovered contributing to Aǃ 
detoxification. Aǃ clearance is achieved via transport over the blood brain barrier, 
enzymatic degradation and phagocytosis by microglia. Recently, several enzymes have been 
discovered which degrade Aǃ, e.g. insulin degrading enzyme (IDE), endothelin converting 
enzyme (ECE), neprilysin, and angiotensin converting enzyme (ACE). The expression of IDE 
is activated by IR and IGF-1R signalling (Zhao et al. 2004). Transport across the blood brain 
barrier (BBB) is mediated by distinct receptors. This transport is achieved via binding to the 
low-density lipoprotein receptor related protein (LRP). The binding of Aǃ to LRP occurs 
directly or in complex with APOE (apolipoprotein E) and/or ǂ2-macroglobulin (ǂ2M). After 
crossing the BBB, Aǃ is transported to peripheral tissues for degradation, for example the 
liver (Tanzi, Moir, and Wagner 2004). It has been proposed that high IGF-1 levels cause 
degradation or clearance of Aǃ. Tg2576 mice present decreased IGF-1 levels compared to 
wild type mice. The treatment with IGF-1 yield to increased transport of Aǃ from the brain, 
possibly via the choroid plexus (Carro et al. 2002). Accordingly, the inactivation of the IGF-
1R signalling in the choroid plexus caused AD-like pathology (Carro et al. 2006). In contrast, 
studies in rats and Tg2576 mice using acute, subchronic and chronic IGF-1 treatment found 
no changes in tau phosphorylation and Aǃ concentrations (Lanz et al. 2008). Possibly, 
chronic peripheral treatment with IGF-1 causes downregulation of the IGF-1R signalling 
pathway as it has been shown for a cohort of individuals with high serum IGF-1 level but 
low IGF-1R signalling (Suh et al. 2008). This might explain the conflicting results of the 
different studies. AD mouse models with induced insulin resistance via high fat diet 
displayed an exacerbation of amyloid pathology (Ho et al. 2004).  
The different studies dealing with IR/IGF-1R signalling and AD prove a connection 
between this signalling pathways and AD pathology. However, the exact molecular 
mechanisms need to be elucidated. 
6. IGF-1 in the brain and ageing 
IR/IGF-1R signalling is a conserved pathway functioning in development, fertility (Liang et 
al. 2003; Tatar, Bartke, and Antebi 2003; Broughton et al. 2005), growth (Butler and Le Roith 
2001; Ikeya et al. 2002) and metabolic regulation (Saltiel and Kahn 2001). Decreased IR/IGF-
1R signalling causes lifespan extension in model organisms like Drosophila melanogaster, 
Caenorhabditis elegans and Mus musculus (Clancy et al. 2001; Holzenberger et al. 2003; Tatar  
et al. 2001).  
The life expenctancy of humans has been increased upon environmental amelioration 
(Wilmoth 2000). However, this is accompanied by an increase of age associated disorders. 
Therefore, the study of the molecular mechanism of ageing might lead to identification of 
disease modifying pathways. One of these pathways is the IR/IGF-1R signalling cascade. 
Studies investigating temporal or spatial restricted changes of the IR/IGF-1R signalling 
pathway in different model organisms, using the RU486-induced GAL4/UAS (upstream 
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activation sequence) in Drosophila, as well as RNAi (RNA interference) incorparation via 
feeding of bacteria to C. elegans and Cre/loxP system in mice (Roman et al. 2001; Sauer 
1998), have been performed. 
The CNS is responsible for endocrine release of insulin-like peptides which activate the 
IR/IGF-1R signalling cascade and subsequently shorten lifespan (Ikeya et al. 2002; 
Broughton et al. 2005). Confusingly, acute increase of IR/IGF1-R signalling is 
neuroprotective but reduction of the signalling causes lifespan extension (Bateman and 
McNeill 2006; Chrysis et al. 2001). 
6.1 IGF-1 signalling in C. elegans 
The impact of IR/IGF-1R-like signalling (IIS) pathway on lifespan was first discovered in  
C. elegans. IIS in C. elegans is similar to the pathway in mammals (Taguchi and White 2008). 
It is activated through binding of insulin-like peptides (INS) to DAF-2 (abnormal Dauer 
formation-2), the IR/IGF-1R in worms (Kenyon et al. 1993). Upon stimulation of DAF-2  
an insulin receptor substrate 1 orthologue (IST-1) is recruited to DAF-2 and AGE-1 (AGEing 
alteration-1), orthologue to human p110. P110, the catalytic subunit of PI3K, promotes the 
generation of phosphatidylinositide-triphosphate (PI3,4,5P) which then activates AKT kinase 
family members (Morris, Tissenbaum, and Ruvkun 1996; Kops et al. 1999; Paradis and 
Ruvkun 1998).  
The mutations of DAF-2 and AGE-1 cause lifespan extension in a DAF-16 dependent 
manner which is a forkhead transcription factor in worms (Kenyon et al. 1993; Lin et  
al. 1997; Ogg et al. 1997; Morris, Tissenbaum, and Ruvkun 1996) and homologue to the 
mammalian FoxO1 and FoxO3a.  
AGE-1 and DAF-2 mutant worms show enhanced thermotaxis learning behaviour during 
ageing. This might be due to resistance to neuronal diseases and oxidative stress 
(Murakami 2007).  
The insulin-like peptides (INS)  are  found  throughout the whole body of C. elegans (Pierce 
et al. 2001; Li, Kennedy, and Ruvkun 2003). Specific sensory neurons regulate lifespan 
through DAF-16 (Alcedo and Kenyon 2004). The ablation of olfactory neurons causes 
lifespan extension being only partially dependent on DAF-16 indicating  
an involvement of other factors. The regulation of INS is not well analysed, but the sensory 
neurons seem to be the major source of INS for peripheral tissues (Alcedo and Kenyon 
2004).  
A study using tissue-specific expression of AGE-1 and DAF-16 revealed that wild-type 
AGE-1 recovers the extended lifespan of AGE-1 mutants. This was shown for wild-type 
AGE-1 expressed in neurons and the intestine. In addition, wild-type DAF-16 rescues 
reduced lifespan of DAF-16/AGE-1 double mutants when expressed in neurons or intestine. 
Moreover, wild-type DAF-16 exerts its full effect when expressed in neurons and the 
intestine exclusively. However, DAF-16 expression showed only minor effects when 
expressed in other tissues (Broughton and Partridge 2009; Iser, Gami, and Wolkow 2007). 
6.2 IGF-1 signalling in Drosophila melanogaster 
D. melanogaster posseses endocrine tissues, which are similar to mammals (Toivonen and 
Partridge 2009). The median neurosecretory cells (mNSCs) of Drosophila are localised in the 
pars intercerebralis. mNSCs generate three of the seven Drosophila insulin-like peptides 
(DILPs). These mNSCs are functionally similar to ǃ-cells of the pancreas which produce 
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insulin. These neurosecretory cells show an analogue development to the mammalian 
anterior pituitary (Wang et al. 2007). The ablation of mNSCs causes lifespan extension, 
because of the depletion of DILP-2, -3 and -5 (Broughton et al. 2005). In a further study using 
a dominant-negative form of p53 expressed in the CNS of flies, lifespan extension was 
induced (Bauer et al. 2005; Slee, O'Connor, and Lu 2004). This correlates with decreased 
DILP-2 expression and reduced PI3K activity in the periphery (Bauer et al. 2007).  
In addition to ablation of mNSCs, mutation of the insulin-like receptor (InR) or of its 
substrate Chico extends lifespan (Clancy et al. 2001; Tu, Epstein, and Tatar 2002; Tatar et al. 
2001). The activation of the InR causes phosphorylation of dFOXO, which is equivalent to 
nematode DAF-16 and mammalian FoxO1 and FoxO3a (Puig et al. 2003; Junger et al. 2003). 
dFOXO activation in the pericerebral fat body has been shown to regulate ageing. This 
activation of dFOXO reduces the expression of DLP-2 in mNSCs followed by 
downregulation of the InR signalling pathway in peripheral fat tissue (Hwangbo et al. 2004) 
The JNK signalling pathway in neurons enhances stress resistance and lifespan extension 
partially via dFOXO (Essers et al. 2004; Wang, Bohmann, and Jasper 2005). Oxidative stress 
induces JNK signalling and subsequently promotes the nuclear localisation of dFOXO and 
induces expression of antioxidant proteins (Huang and Tindall 2007; Kops et al. 2002). 
Neurons are prone to oxidative stress based on the high production of ROS and low amount 
of antioxidant proteins (Lin and Beal 2006). Peroxiredoxin abolishes hydroperoxide using 
thioredoxin as hydrogen donor, which decreases ROS (reactive oxygen species) (Lim et al. 
1993). Mammalians express six peroxiredoxins (I-VI). Peroxiredoxin II is solely expressed in 
the brain (Jin et al. 2005). Jafrac1, the homologue of the human Peroxiredoxin II (hPrxII), is a 
downstream protein of JNK signalling and target gene of dFOXO in neurons. Jafrac1 
reduces reactive oxygen species (ROS) and extends lifespan (Lee et al. 2009) linking 
decreased IIS to increased clearance of ROS as possible mechanism for lifespan extension. 
6.3 IGF-1 signalling regulates mammalian lifespan 
In mice, it is well known that adult body size is an indicator of GH/IGF-1 actions and 
negatively correlated to longevity (Rollo 2002; Miller et al. 2002). Furthermore, IGF-1 plasma 
levels are negatively correlated with median lifespan (Yuan et al. 2009). Up to date, several 
mouse models of healthy ageing and longevity have been identified and analysed. Most of 
those long-lived mice have alterations within the IIS, GH or mTOR signalling pathway, 
indicating their key-role in influencing the process of ageing itself (Broughton and Partridge 
2009; Kenyon 2010; Kenyon 2005; Piper et al. 2008; Bluher, Kahn, and Kahn 2003; Kappeler 
et al. 2008; Selman et al. 2008). 
Highest impact on lifespan extension seems to have the ablation of GH signalling, as 
mutants with impaired GH action demonstrate higher increase of median and maximal 
lifespan than those with mutations that directly impact IGF-1 signalling (Coschigano et al. 
2000; Coschigano et al. 2003; Brown-Borg et al. 1996; Flurkey et al. 2001). Examples for 
altered GH signalling are the Ames dwarf mice (Prop1def/def), Snell dwarf mice (Pit-1def/def) 
and Laron dwarf mice (GHR-/-). As the transcription factors Prop1 and Pit-1 are also 
essential for induction of thyroidea stimulating hormone (TSH) and prolactin, Ames dwarf 
mice and Snell dwarf mice are not only GH deficient but in addition produce less thyroidea 
stimulating hormone (TSH) and prolactin. Therefore, it can not be excluded that some of the 
effects seen in Ames and Snell dwarf mice might arise through deletion of TSH and 
prolactin. Laron dwarf mice (GHRKO ,GHR-/-) are only resistant to GH signalling, and their 
longevity phenotype has been reproducible in different laboratories on different genetic 
www.intechopen.com
Role of Central Insulin-Like Growth Factor-1  
Receptor Signalling in Ageing and Endocrine Regulation 
 
229 
backgrounds and diets (Coschigano et al. 2003; Bartke and Brown-Borg 2004; Bonkowski et 
al. 2006). 
As described above, GH action is mainly, but not completely, mediated by IGF-1 and 
circulating levels of IGF-1 are drastically reduced in GH-deficient Ames and Snell dwarf 
mice as well as in GH-resistant Laron dwarf mice (Brown-Borg et al. 1996; Coschigano et al. 
2000; Flurkey et al. 2001). This reduction is primarily due to decreased expression of IGF-1 in 
the liver, whereas locally derived IGF-1 is, if at all, less affected (Bartke 2011). Normal 
expression of IGF-1 in the brain, especially in the hippocampus, might explain the 
maintenance of cognitive function in the long-lived mutants of the GH/IGF-1 system 
(Kinney et al. 2001). Besides reduced circulating IGF-1, lower insulin levels and enhanced 
insulin sensitivity are among the most prominent endocrine features shared by Ames dwarf, 
Snell dwarf and GHRKO mice (Bartke 2006) and have been found to be beneficial for ageing 
and survival (Bartke 2011). Additionally, increased adiponectin levels, which are associated 
with improved insulin sensitivity, anti-inflammatory and anti-atherogenic effects, were 
observed in all three mouse lines (Berryman et al. 2004; Wang et al. 2006). GH-deficient  
and -resistant mice were also found to have other phenotypic characteristics through which 
lifespan is thought to be increased, such as resistance to oxidative and other cytotoxic 
stresses (Bartke et al. 2001; Murakami, Salmon, and Miller 2003), increased activity of 
antioxidant enzymes (Hauck et al. 2002; Bartke et al. 2001; Romanick, Rakoczy, and Brown-
Borg 2004), reduced body temperature (Hunter et al. 1999; Hauck et al. 2001) and reduced 
susceptibility to cancer (Yang et al. 1996; Deitel et al. 2002; Ikeno et al. 2003).  
Another model for extended healthy lifespan in mammals is the fat-specific insulin receptor 
knockout (FIRKO) mouse (Bluher, Kahn, and Kahn 2003). These mutant mice maintain low 
body fat despite normal food intake, have normal lipid metabolism and demonstrate 
improved glucose tolerance and insulin sensitivity throughout life (Bluher, Kahn, and Kahn 
2003). The underlying mechanisms of this model are not well understood and apart from 
impaired IR signalling, altered inflammatory state and mitochondrial activity in these 
animals are discussed. 
A remarkable increase of mean and maximal lifespan has been found in female and male 
mice lacking PAPP-A. PAPP-A is a metalloproteinase that cleaves inhibitory IGFBPs (as 
described above), thereby increasing local bioavailability of IGF-1 without altering IGF-1 
expression (Lawrence et al. 1999). Conversely, deletion of PAPP-A in PAPP-A-/- mice results 
in reduced local IGF-1 levels, and thus PAPP-A-/- mice are born as dwarfs (Conover et al. 
2004). In these mutants, extension of lifespan was not associated with impaired glucose or 
fat metabolism and serum IGF-1, insulin and GH levels were unaltered (Conover and Bale 
2007). However, these mice have markedly reduced incidence of spontaneous tumors 
(Conover and Bale 2007) and were found to be resistant to develop experimentally induced 
neointimal hyperplasia and atherosclerosis (Harrington, Simari, and Conover 2007; Resch, 
Simari, and Conover 2006). 
As described above, homozygous deletion of the IGF-1R or IGF-1 is lethal or produces 
severe developmental defects, however extended lifespan was reported in mice with 
heterozygous deletion of the IGF-1R (IGF-1R+/-) (Holzenberger et al. 2003). IGF-1R+/- mice 
have upregulated serum IGF-1 levels, which might indicate an endocrine compensatory 
response to the reduced numbers of IGF-1R, and these mice do not develop dwarfism 
(Holzenberger et al. 2003). Those mutants have no alterations in energy metabolism, 
physical activity, fertility and reproduction but display greater resistance to oxidative stress 
(Holzenberger et al. 2003) probably causing the observed lifespan extension, which is 
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predominantly seen in females. As described earlier, the selective reduction of IGF-1 
signalling in the brain of bIGF1R+/- mice leads to an increase in median but not maximal 
lifespan (Kappeler et al. 2008). 
The knockout models for IRS-proteins provide evidence that interference with IGF-
1/insulin signalling downstream of the IGF-1 and insulin receptor influences lifespan in 
mice. Female IRS-1 knockout (IRS-1-/-) mice were reported to be long-lived and resistant to a 
number of conditions related to neurological and neuromuscular, immune, skin and bone 
disease (Selman et al. 2008). In these animals, body weight including fat mass was reduced, 
but endocrine function of the pituitary as well as circulating IGF-1 levels were preserved 
(Selman et al. 2008). Additionally, female IRS-1-/- mice were hyperinsulinemic and IGF-
1/insulin resistant and rectal temperature was significantly elevated (Selman et al. 2008). All 
these characteristics are in contrast to the long-lived GH-deficient and GH-resistant mice, 
however female IRS-1-/- mutants have similar alterations in expression of genes involved in 
oxidative stress defence and DNA repair (Selman et al. 2008). In the same study, no 
significant increase of lifespan was found for male IRS-1-/- mice, as well as for IRS-1+/- and 
IRS-2+/- mice of both sexes, and IRS-2-/- mice were even short-lived (Selman et al. 2008). 
IRS-2+/- mice were found to be long-lived, slightly larger and more insulin sensitive and 
glucose tolerant than wild-type mice (Taguchi, Wartschow, and White 2007). However, the 
animals studied by Selman et al. (2008) were fed a ‘standard’ rodent diet with a fat content 
of 5 %, while those studied by Taguchi et al. (2007) were on a ‘high energy’ diet with a fat 
content of 9 %, hence indicating that the IRS-2+/- mice might be protected from the harming 
effects of a high-fat diet (Bartke 2008). In addition, Taguchi et al. (2007) reported that brain 
specific alterations of IRS-2 in bIRS-2+/- and bIRS-2-/- mice result in increased lifespan 
despite glucose and insulin resistance (Taguchi, Wartschow, and White 2007). Further work 
will be needed to clarify and reconcile the observations made in those two laboratories 
(Bartke 2008). 
Regardless the criticism on the reproducibility of the observations made by Holzenberger 
(Kappeler et al. 2008) and Taguchi (2007), they provide evidence that selective disruption of 
the IIS pathway in neurons might not only extend lifespan in C.elegans and Drosophila 
(Wolkow et al. 2000; Kenyon 2005) but also in mammals. These findings may indirectly be 
verified by other studies that demonstrate a protection from AD pathology in a transgenic 
AD mouse model via deletion of IGF-1R or IRS-2 (Cohen et al. 2009; Freude et al. 2009; 
Killick et al. 2009). 
6.4 IGF-1 signalling and its relevance to human longevity 
The IIS pathway is highly conserved throughout evolution from nematodes and flies to 
mammals. In the last years, an increasing body of data suggests that this pathway is 
important for human longevity as well.  
GH secretion and IGF-1 levels decrease with age (Rudman et al. 1981), which contributes to 
ageing-associated changes in body composition such as increased adipose tissue and 
reduced lean body mass leading to impaired insulin sensitivity and cardiovascular disease. 
The same observations are made in patients with GH deficiency (Khan et al. 2001) and 
mutation in the GHR gene: Low serum IGF-1 levels, short stature, obesity, glucose 
intolerance and possible mental retardation but no decrease in life expectancy (Rincon, 
Rudin, and Barzilai 2005). Conversely, pathologic GH excess in acromegaly leads to reduced 
life expectancy due to cardiovascular disease, diabetes and malignancies (Orme et al. 1998). 
Additionally, body height has been identified as a cancer risk in a number of large 
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population studies (Bartke 2011) and serum IGF-1 levels correlate with cancer mortality in 
elderly men (Major et al. 2010). Therefore, the decline of GH secretion in the process of 
ageing might not simply reflect a progressive failure of the hypothalamus-somatotrope axis, 
but might be protective for the development of insulin resistance and cancer (Bartke 2003; 
Shechter et al. 2007). GH/IGF-1 therapy in elderly and GH deficient patients improves the 
ratio of lean and fat body mass, the lipid profile, protein synthesis, bone density, immune 
functions and memory (Khan et al. 2001), but certainly bears adverse side-effects, as GH is 
known to be diabetogenic and IGF-1 might increase the risk of cancer (Juul 1999; Khan et al. 
2001; Pollak, Schernhammer, and Hankinson 2004; Major et al. 2010).  
 
 
Fig. 4. GH/IGF-1 in ageing 
Serum levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) decrease 
during ageing contributing to increased fat mass and decreased lean mass and might 
influence cognitive function negatively. Serum insulin levels increase with age indicating 
age-associated insulin insensitivity possibly leading to impaired glucose tolerance and 
diabetes. 
Recently, a study on a cohort of Ecuadorian patients carrying mutations in the GHR gene 
was published after 22 years of monitoring. Patients demonstrated severe GH resistance and 
reduced circulating IGF-1 and IGF-2 levels resulting in short stature (Guevara-Aguirre et al. 
2011). No extension in lifespan was found in this cohort, which is in contrast to the GHR 
deficient mouse model (Guevara-Aguirre et al. 2011). However, causes of death were 
different in unaffected relatives compared to GHR deficient subjects, which died much more 
frequently from accidents, alcohol-related diseases and convulsive disorders, which might 
be the reason for unchanged lifespan (Guevara-Aguirre et al. 2011). Cancer accounted for 17 
% and diabetes for 5 % of all diseases in non-affected relatives, whereas only one nonlethal 
malignancy and no cases of diabetes, probably due to improved insulin sensitivity, were 
reported for the individuals with GHR mutations (Guevara-Aguirre et al. 2011). 
Importantly, GHR deficient subjects appear to have no increased mortality from vascular 
diseases compared to their relatives (30 % of deaths verses 33 % of deaths in the non-
affected relatives), however the proportion of strokes (3 % verses 12 %) and cardiac disease 
(27 % verses 21 %) was slightly different (Guevara-Aguirre et al. 2011).  
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In a cohort of Ashkenazi Jewish centenarians, a gender-specific increase in serum IGF-1 
associated with smaller stature in female offspring was found to be due to heterozygous 
mutations in the IGF-1R gene (Suh et al. 2008). These rare mutations were significantly 
more common in female centenarians and overrepresented compared to controls (Suh et 
al. 2008). These observations are in line with the IGF-1R+/- mouse model, in which female 
mice show growth retardation and extended lifespan (Holzenberger et al. 2003) but IGF-1 
resistance. 
Further studies on human centenarians, mainly screening selectively genes of the IIS 
pathway, identified certain genes in the insulin/IGF-1 pathway to be important for human 
longevity. Several cohorts with different genetic background have reported an association of 
FOXO3A single nucleotide polymorphisms (SNPs) with longevity (Willcox et al. 2008; 
Flachsbart et al. 2009; Anselmi et al. 2009; Pawlikowska et al. 2009; Li et al. 2009). 
Interestingly, the study on long-lived Han Chinese revealed a SNP of FOXO1 associated 
with female longevity exclusively (Li et al. 2009).  
Furthermore, in the Leiden 85-plus Study an association of a certain FOXO1 haplotype with 
higher HbA1c levels, higher prevalence of diabetes, myocardial infarction as well as 
increased mortality was observed (Kuningas et al. 2007). In addition, a certain haplotype of 
the FOXO3A gene revealed increased risks for stroke and mortality (Kuningas et al. 2007). 
These findings indicate that alterations within the FOXO genes might be causative involved 
in age-associated diseases and regulation of lifespan (Flachsbart et al. 2009). 
7. Conclusion 
Recent studies in different model organisms, including C. elegans, Drosophila melanogaster 
and Mus musculus have generated piling knowledge about the IIS pathway and its relevance 
for healthy ageing and longevity. The data obtained in these model organisms have been 
translated to humans and lead to the identification of the IIS pathway as regulator for 
human lifespan and ageing. 
The GH and IGF-1 signalling pathway plays a key-role in regulating growth and 
metabolism, and  alterations within this pathway have crucial effects on health and lifespan. 
Model-organisms with reduced GH or IGF-1 signalling are frequently long-lived or show an 
increased mean lifespan. Interestingly, serum GH and IGF-1 levels decrease with age, and 
this might be interpreted not solely as progressive failure of the hypothalamus-somatotrope 
axis but rather as protection for insulin resistance and malignancies.  
IGF-1R signalling is required for normal brain development, and acute IGF-1 action might 
enhance cognitive functions and ameliorates ischemic or traumatic brain injuries. 
Additionally, recent studies demonstrate that IGF-1R signalling or the number of IGF-1Rs in 
the brain during early development determines metabolism and possibly age-associated 
diseases indicating a role of IGF-1 mediated signals as neuroendocrine regulator of health 
and lifespan. 
Foxo-transcription factors have been identified as main downstream-target of IIS and seem 
to be essential for activating gene transcripton that mediates longevity. Furthermore, 
genomic screening of centenarians with different genetic background found matching SNPs 
or haplotypes in the FOXO3A gene suggesting a key-role of FOXO3A in influencing lifespan 
not only in model organisms but also in humans.  
However, the role of IIS in AD still raises questions, as the impaired signalling might be 
cause or consequence of neurodegeneration. 
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Therapeutic approaches altering the IIS pathway might not only improve treatment of 
neurodegenerative disorders but provide a possibility to prevent ageing-associated diseases 
in the future.  
8. References 
Alcedo, J., and C. Kenyon. (2004). Regulation of C. elegans longevity by specific gustatory and 
olfactory neurons. Neuron 41 (1):45-55. 
Alessi, D. R., M. Andjelkovic, B. Caudwell, P. Cron, N. Morrice, P. Cohen, and B. A. 
Hemmings. (1996). Mechanism of activation of protein kinase B by insulin and IGF-1. 
EMBO J 15 (23):6541-51. 
Altman, J., and S. A. Bayer. (1990). Migration and distribution of two populations of 
hippocampal granule cell precursors during the perinatal and postnatal periods. J 
Comp Neurol 301 (3):365-81. 
Altman, J., and S. A. Bayer. (1990). Mosaic organization of the hippocampal neuroepithelium 
and the multiple germinal sources of dentate granule cells. J Comp Neurol 301 (3):325-
42. 
Alzheimer, A., R. A. Stelzmann, H. N. Schnitzlein, and F. R. Murtagh. (1995). An English 
translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der 
Hirnrinde". Clin Anat 8 (6):429-31. 
Anselmi, C. V., A. Malovini, R. Roncarati, V. Novelli, F. Villa, G. Condorelli, R. Bellazzi, and A. 
A. Puca. (2009). Association of the FOXO3A locus with extreme longevity in a 
southern Italian centenarian study. Rejuvenation Res 12 (2):95-104. 
Arimon, M., I. Diez-Perez, M. J. Kogan, N. Durany, E. Giralt, F. Sanz, and X. Fernandez-
Busquets. (2005). Fine structure study of Abeta1-42 fibrillogenesis with atomic force 
microscopy. FASEB J 19 (10):1344-6. 
Astrinidis, A., and E. P. Henske. (2005). Tuberous sclerosis complex: linking growth and 
energy signaling pathways with human disease. Oncogene 24 (50):7475-81. 
Baker, J., J. P. Liu, E. J. Robertson, and A. Efstratiadis. (1993). Role of insulin-like growth factors 
in embryonic and postnatal growth. Cell 75 (1):73-82. 
Ballard, F. J., J. C. Wallace, G. L. Francis, L. C. Read, and F. M. Tomas. (1996). Des(1-3)IGF-I: a 
truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol 28 (10):1085-7. 
Ballatore, C., V. M. Lee, and J. Q. Trojanowski. (2007). Tau-mediated neurodegeneration in 
Alzheimer's disease and related disorders. Nat Rev Neurosci 8 (9):663-72. 
Barrow, C. J., and M. G. Zagorski. (1991). Solution structures of beta peptide and its constituent 
fragments: relation to amyloid deposition. Science 253 (5016):179-82. 
Bartke, A. (2003). Is growth hormone deficiency a beneficial adaptation to aging? Evidence 
from experimental animals. Trends Endocrinol Metab 14 (7):340-4. 
Bartke, A. (2006). New findings in transgenic, gene knockout and mutant mice. Exp Gerontol 41 
(12):1217-9. 
Bartke, A. (2008). Impact of reduced insulin-like growth factor-1/insulin signaling on aging in 
mammals: novel findings. Aging Cell 7 (3):285-90. 
Bartke, A. (2011). Growth hormone, insulin and aging: the benefits of endocrine defects. Exp 
Gerontol 46 (2-3):108-11. 
Bartke, A., and H. Brown-Borg. (2004). Life extension in the dwarf mouse. Curr Top Dev Biol 
63:189-225. 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
234 
Bartke, A., H. Brown-Borg, J. Mattison, B. Kinney, S. Hauck, and C. Wright. (2001). Prolonged 
longevity of hypopituitary dwarf mice. Exp Gerontol 36 (1):21-8. 
Bateman, J. M., and H. McNeill. (2006). Insulin/IGF signalling in neurogenesis. Cell Mol Life Sci 
63 (15):1701-5. 
Bauer, J. H., C. Chang, S. N. Morris, S. Hozier, S. Andersen, J. S. Waitzman, and S. L. Helfand. 
(2007). Expression of dominant-negative Dmp53 in the adult fly brain inhibits insulin 
signaling. Proc Natl Acad Sci U S A 104 (33):13355-60. 
Bauer, J. H., P. C. Poon, H. Glatt-Deeley, J. M. Abrams, and S. L. Helfand. (2005). Neuronal 
expression of p53 dominant-negative proteins in adult Drosophila melanogaster 
extends life span. Curr Biol 15 (22):2063-8. 
Baxter, R. C. (1988). Characterization of the acid-labile subunit of the growth hormone-
dependent insulin-like growth factor binding protein complex. J Clin Endocrinol Metab 
67 (2):265-72. 
Baxter, R. C. (2000). Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs 
and intrinsic bioactivities. Am J Physiol Endocrinol Metab 278 (6):E967-76. 
Baxter, R. C., and J. L. Martin. (1989). Structure of the Mr 140,000 growth hormone-dependent 
insulin-like growth factor binding protein complex: determination by reconstitution 
and affinity-labeling. Proc Natl Acad Sci U S A 86 (18):6898-902. 
Baxter, R. C., J. L. Martin, and V. A. Beniac. (1989). High molecular weight insulin-like growth 
factor binding protein complex. Purification and properties of the acid-labile subunit 
from human serum. J Biol Chem 264 (20):11843-8. 
Baxter, R. C., S. Meka, and S. M. Firth. (2002). Molecular distribution of IGF binding protein-5 
in human serum. J Clin Endocrinol Metab 87 (1):271-6. 
Beck, K. D., L. Powell-Braxton, H. R. Widmer, J. Valverde, and F. Hefti. (1995). Igf1 gene 
disruption results in reduced brain size, CNS hypomyelination, and loss of 
hippocampal granule and striatal parvalbumin-containing neurons. Neuron 14 
(4):717-30. 
Berryman, D. E., E. O. List, K. T. Coschigano, K. Behar, J. K. Kim, and J. J. Kopchick. (2004). 
Comparing adiposity profiles in three mouse models with altered GH signaling. 
Growth Horm IGF Res 14 (4):309-18. 
Berryman, D. E., E. O. List, D. T. Kohn, K. T. Coschigano, R. J. Seeley, and J. J. Kopchick. (2006). 
Effect of growth hormone on susceptibility to diet-induced obesity. Endocrinology 147 
(6):2801-8. 
Bertolotto, C., L. Maulon, N. Filippa, G. Baier, and P. Auberger. (2000). Protein kinase C theta 
and epsilon promote T-cell survival by a rsk-dependent phosphorylation and 
inactivation of BAD. J Biol Chem 275 (47):37246-50. 
Bertram, L., and R. E. Tanzi. (2005). The genetic epidemiology of neurodegenerative disease. J 
Clin Invest 115 (6):1449-57. 
Bick, T., Z. Hochberg, T. Amit, O. G. Isaksson, and J. O. Jansson. (1992). Roles of pulsatility and 
continuity of growth hormone (GH) administration in the regulation of hepatic GH-
receptors, and circulating GH-binding protein and insulin-like growth factor-I. 
Endocrinology 131 (1):423-9. 
Biggs, W. H., 3rd, J. Meisenhelder, T. Hunter, W. K. Cavenee, and K. C. Arden. (1999). Protein 
kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged 
helix transcription factor FKHR1. Proc Natl Acad Sci U S A 96 (13):7421-6. 
www.intechopen.com
Role of Central Insulin-Like Growth Factor-1  
Receptor Signalling in Ageing and Endocrine Regulation 
 
235 
Birkenkamp, K. U., and P. J. Coffer. (2003). Regulation of cell survival and proliferation by the 
FOXO (Forkhead box, class O) subfamily of Forkhead transcription factors. Biochem 
Soc Trans 31 (Pt 1):292-7. 
Bluher, M., B. B. Kahn, and C. R. Kahn. (2003). Extended longevity in mice lacking the insulin 
receptor in adipose tissue. Science 299 (5606):572-4. 
Bohannon, N. J., E. S. Corp, B. J. Wilcox, D. P. Figlewicz, D. M. Dorsa, and D. G. Baskin. (1988). 
Characterization of insulin-like growth factor I receptors in the median eminence of 
the brain and their modulation by food restriction. Endocrinology 122 (5):1940-7. 
Bohlooly, Y. M., B. Olsson, A. Gritli-Linde, O. Brusehed, O. G. Isaksson, C. Ohlsson, B. 
Soderpalm, and J. Tornell. (2001). Enhanced spontaneous locomotor activity in bovine 
GH transgenic mice involves peripheral mechanisms. Endocrinology 142 (10):4560-7. 
Boisclair, Y. R., R. P. Rhoads, I. Ueki, J. Wang, and G. T. Ooi. (2001). The acid-labile subunit 
(ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten 
component of the circulating IGF system. J Endocrinol 170 (1):63-70. 
Bondy, C. A., and W. H. Lee. (1993). Patterns of insulin-like growth factor and IGF receptor 
gene expression in the brain. Functional implications. Ann N Y Acad Sci 692:33-43. 
Bondy, C. A., H. Werner, C. T. Roberts, Jr., and D. LeRoith. (1990). Cellular pattern of insulin-
like growth factor-I (IGF-I) and type I IGF receptor gene expression in early 
organogenesis: comparison with IGF-II gene expression. Mol Endocrinol 4 (9):1386-98. 
Bondy, C., and W. H. Lee. (1993). Correlation between insulin-like growth factor (IGF)-binding 
protein 5 and IGF-I gene expression during brain development. J Neurosci 13 
(12):5092-104. 
Bondy, C., H. Werner, C. T. Roberts, Jr., and D. LeRoith. (1992). Cellular pattern of type-I 
insulin-like growth factor receptor gene expression during maturation of the rat 
brain: comparison with insulin-like growth factors I and II. Neuroscience 46 (4):909-23. 
Bonkowski, M. S., R. W. Pamenter, J. S. Rocha, M. M. Masternak, J. A. Panici, and A. Bartke. 
(2006). Long-lived growth hormone receptor knockout mice show a delay in age-
related changes of body composition and bone characteristics. J Gerontol A Biol Sci 
Med Sci 61 (6):562-7. 
Boura-Halfon, S., and Y. Zick. (2009). Phosphorylation of IRS proteins, insulin action, and 
insulin resistance. Am J Physiol Endocrinol Metab 296 (4):E581-91. 
Braulke, T. (1999). Type-2 IGF receptor: a multi-ligand binding protein. Horm Metab Res 31 (2-
3):242-6. 
Broughton, S. J., M. D. Piper, T. Ikeya, T. M. Bass, J. Jacobson, Y. Driege, P. Martinez, E. Hafen, 
D. J. Withers, S. J. Leevers, and L. Partridge. (2005). Longer lifespan, altered 
metabolism, and stress resistance in Drosophila from ablation of cells making insulin-
like ligands. Proc Natl Acad Sci U S A 102 (8):3105-10. 
Broughton, S., and L. Partridge. (2009). Insulin/IGF-like signalling, the central nervous system 
and aging. Biochem J 418 (1):1-12. 
Brown-Borg, H. M., K. E. Borg, C. J. Meliska, and A. Bartke. (1996). Dwarf mice and the ageing 
process. Nature 384 (6604):33. 
Brunet, A., A. Bonni, M. J. Zigmond, M. Z. Lin, P. Juo, L. S. Hu, M. J. Anderson, K. C. Arden, J. 
Blenis, and M. E. Greenberg. (1999). Akt promotes cell survival by phosphorylating 
and inhibiting a Forkhead transcription factor. Cell 96 (6):857-68. 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
236 
Brunet, A., D. Roux, P. Lenormand, S. Dowd, S. Keyse, and J. Pouyssegur. (1999). Nuclear 
translocation of p42/p44 mitogen-activated protein kinase is required for growth 
factor-induced gene expression and cell cycle entry. EMBO J 18 (3):664-74. 
Brunet, A., L. B. Sweeney, J. F. Sturgill, K. F. Chua, P. L. Greer, Y. Lin, H. Tran, S. E. Ross, R. 
Mostoslavsky, H. Y. Cohen, L. S. Hu, H. L. Cheng, M. P. Jedrychowski, S. P. Gygi, D. 
A. Sinclair, F. W. Alt, and M. E. Greenberg. (2004). Stress-dependent regulation of 
FOXO transcription factors by the SIRT1 deacetylase. Science 303 (5666):2011-5. 
Bruning, J. C., D. Gautam, D. J. Burks, J. Gillette, M. Schubert, P. C. Orban, R. Klein, W. Krone, 
D. Muller-Wieland, and C. R. Kahn. (2000). Role of brain insulin receptor in control of 
body weight and reproduction. Science 289 (5487):2122-5. 
Busby, W. H., Jr., T. J. Nam, A. Moralez, C. Smith, M. Jennings, and D. R. Clemmons. (2000). 
The complement component C1s is the protease that accounts for cleavage of insulin-
like growth factor-binding protein-5 in fibroblast medium. J Biol Chem 275 (48):37638-
44. 
Butler, A. A., and D. Le Roith. (2001). Control of growth by the somatropic axis: growth 
hormone and the insulin-like growth factors have related and independent roles. 
Annu Rev Physiol 63:141-64. 
Butler, A. A., and D. LeRoith. (2001). Minireview: tissue-specific versus generalized gene 
targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor 
physiology. Endocrinology 142 (5):1685-8. 
Byun, D., S. Mohan, M. Yoo, C. Sexton, D. J. Baylink, and X. Qin. (2001). Pregnancy-associated 
plasma protein-A accounts for the insulin-like growth factor (IGF)-binding protein-4 
(IGFBP-4) proteolytic activity in human pregnancy serum and enhances the 
mitogenic activity of IGF by degrading IGFBP-4 in vitro. J Clin Endocrinol Metab 86 
(2):847-54. 
Carlsson-Skwirut, C., M. Lake, M. Hartmanis, K. Hall, and V. R. Sara. (1989). A comparison of 
the biological activity of the recombinant intact and truncated insulin-like growth 
factor 1 (IGF-1). Biochim Biophys Acta 1011 (2-3):192-7. 
Carlsson, L., and J. O. Jansson. (1990). Endogenous growth hormone (GH) secretion in male 
rats is synchronized to pulsatile GH infusions given at 3-hour intervals. Endocrinology 
126 (1):6-10. 
Carro, E., A. Nunez, S. Busiguina, and I. Torres-Aleman. (2000). Circulating insulin-like 
growth factor I mediates effects of exercise on the brain. J Neurosci 20 (8):2926-33. 
Carro, E., C. Spuch, J. L. Trejo, D. Antequera, and I. Torres-Aleman. (2005). Choroid plexus 
megalin is involved in neuroprotection by serum insulin-like growth factor I. J 
Neurosci 25 (47):10884-93. 
Carro, E., J. L. Trejo, T. Gomez-Isla, D. LeRoith, and I. Torres-Aleman. (2002). Serum insulin-
like growth factor I regulates brain amyloid-beta levels. Nat Med 8 (12):1390-7. 
Carro, E., J. L. Trejo, C. Spuch, D. Bohl, J. M. Heard, and I. Torres-Aleman. (2006). Blockade of 
the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-
like neuropathology in rodents: new cues into the human disease? Neurobiol Aging 27 
(11):1618-31. 
Carson, M. J., R. R. Behringer, R. L. Brinster, and F. A. McMorris. (1993). Insulin-like growth 
factor I increases brain growth and central nervous system myelination in transgenic 
mice. Neuron 10 (4):729-40. 
www.intechopen.com
Role of Central Insulin-Like Growth Factor-1  
Receptor Signalling in Ageing and Endocrine Regulation 
 
237 
Cheatham, B., and C. R. Kahn. (1995). Insulin action and the insulin signaling network. Endocr 
Rev 16 (2):117-42. 
Chen, J., P. R. Somanath, O. Razorenova, W. S. Chen, N. Hay, P. Bornstein, and T. V. Byzova. 
(2005). Akt1 regulates pathological angiogenesis, vascular maturation and 
permeability in vivo. Nat Med 11 (11):1188-96. 
Cheng, C. M., V. Tseng, J. Wang, D. Wang, L. Matyakhina, and C. A. Bondy. (2005). Tau is 
hyperphosphorylated in the insulin-like growth factor-I null brain. Endocrinology 146 
(12):5086-91. 
Cho, J. H., and G. V. Johnson. (2004). Primed phosphorylation of tau at Thr231 by glycogen 
synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to 
bind and stabilize microtubules. J Neurochem 88 (2):349-58. 
Chou, C. K., T. J. Dull, D. S. Russell, R. Gherzi, D. Lebwohl, A. Ullrich, and O. M. Rosen. (1987). 
Human insulin receptors mutated at the ATP-binding site lack protein tyrosine 
kinase activity and fail to mediate postreceptor effects of insulin. J Biol Chem 262 
(4):1842-7. 
Chromy, B. A., R. J. Nowak, M. P. Lambert, K. L. Viola, L. Chang, P. T. Velasco, B. W. Jones, S. 
J. Fernandez, P. N. Lacor, P. Horowitz, C. E. Finch, G. A. Krafft, and W. L. Klein. 
(2003). Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42 
(44):12749-60. 
Chrysis, D., A. S. Calikoglu, P. Ye, and A. J. D'Ercole. (2001). Insulin-like growth factor-I 
overexpression attenuates cerebellar apoptosis by altering the expression of Bcl 
family proteins in a developmentally specific manner. J Neurosci 21 (5):1481-9. 
Citron, M. (2002). Alzheimer's disease: treatments in discovery and development. Nat Neurosci 
5 Suppl:1055-7. 
Clancy, D. J., D. Gems, L. G. Harshman, S. Oldham, H. Stocker, E. Hafen, S. J. Leevers, and L. 
Partridge. (2001). Extension of life-span by loss of CHICO, a Drosophila insulin 
receptor substrate protein. Science 292 (5514):104-6. 
Clark, K. L., E. D. Halay, E. Lai, and S. K. Burley. (1993). Co-crystal structure of the HNF-
3/fork head DNA-recognition motif resembles histone H5. Nature 364 (6436):412-20. 
Clark, R. G., J. O. Jansson, O. Isaksson, and I. C. Robinson. (1985). Intravenous growth 
hormone: growth responses to patterned infusions in hypophysectomized rats. J 
Endocrinol 104 (1):53-61. 
Cleary, J. P., D. M. Walsh, J. J. Hofmeister, G. M. Shankar, M. A. Kuskowski, D. J. Selkoe, and 
K. H. Ashe. (2005). Natural oligomers of the amyloid-beta protein specifically disrupt 
cognitive function. Nat Neurosci 8 (1):79-84. 
Cohen, E., J. Bieschke, R. M. Perciavalle, J. W. Kelly, and A. Dillin. (2006). Opposing activities 
protect against age-onset proteotoxicity. Science 313 (5793):1604-10. 
Cohen, E., J. F. Paulsson, P. Blinder, T. Burstyn-Cohen, D. Du, G. Estepa, A. Adame, H. M. 
Pham, M. Holzenberger, J. W. Kelly, E. Masliah, and A. Dillin. (2009). Reduced IGF-1 
signaling delays age-associated proteotoxicity in mice. Cell 139 (6):1157-69. 
Cohick, W. S., and D. R. Clemmons. (1993). The insulin-like growth factors. Annu Rev Physiol 
55:131-53. 
Cole, A. R., A. Astell, C. Green, and C. Sutherland. (2007). Molecular connexions between 
dementia and diabetes. Neurosci Biobehav Rev 31 (7):1046-63. 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
238 
Coles, M., W. Bicknell, A. A. Watson, D. P. Fairlie, and D. J. Craik. (1998). Solution structure of 
amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-
spanning domain where we think it is? Biochemistry 37 (31):11064-77. 
Conover, C. A. (1995). Insulin-like growth factor binding protein proteolysis in bone cell 
models. Prog Growth Factor Res 6 (2-4):301-9. 
Conover, C. A., and L. K. Bale. (2007). Loss of pregnancy-associated plasma protein A extends 
lifespan in mice. Aging Cell 6 (5):727-9. 
Conover, C. A., L. K. Bale, M. T. Overgaard, E. W. Johnstone, U. H. Laursen, E. M. Fuchtbauer, 
C. Oxvig, and J. van Deursen. (2004). Metalloproteinase pregnancy-associated plasma 
protein A is a critical growth regulatory factor during fetal development. Development 
131 (5):1187-94. 
Conover, C. A., G. F. Faessen, K. E. Ilg, Y. A. Chandrasekher, M. Christiansen, M. T. 
Overgaard, C. Oxvig, and L. C. Giudice. (2001). Pregnancy-associated plasma protein-
a is the insulin-like growth factor binding protein-4 protease secreted by human 
ovarian granulosa cells and is a marker of dominant follicle selection and the corpus 
luteum. Endocrinology 142 (5):2155. 
Coschigano, K. T., D. Clemmons, L. L. Bellush, and J. J. Kopchick. (2000). Assessment of 
growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology 141 
(7):2608-13. 
Coschigano, K. T., A. N. Holland, M. E. Riders, E. O. List, A. Flyvbjerg, and J. J. Kopchick. 
(2003). Deletion, but not antagonism, of the mouse growth hormone receptor results 
in severely decreased body weights, insulin, and insulin-like growth factor I levels 
and increased life span. Endocrinology 144 (9):3799-810. 
Costantini, C., H. Scrable, and L. Puglielli. (2006). An aging pathway controls the TrkA to 
p75NTR receptor switch and amyloid beta-peptide generation. EMBO J 25 (9):1997-
2006. 
Couce, M. E., A. J. Weatherington, and J. F. McGinty. (1992). Expression of insulin-like growth 
factor-II (IGF-II) and IGF-II/mannose-6-phosphate receptor in the rat hippocampus: 
an in situ hybridization and immunocytochemical study. Endocrinology 131 (4):1636-
42. 
Crescenzi, O., S. Tomaselli, R. Guerrini, S. Salvadori, A. M. D'Ursi, P. A. Temussi, and D. 
Picone. (2002). Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an 
apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem 269 
(22):5642-8. 
D'Ercole, A. J., Z. Dai, Y. Xing, C. Boney, M. B. Wilkie, J. M. Lauder, V. K. Han, and D. R. 
Clemmons. (1994). Brain growth retardation due to the expression of human insulin 
like growth factor binding protein-1 in transgenic mice: an in vivo model for the 
analysis of igf function in the brain. Brain Res Dev Brain Res 82 (1-2):213-22. 
Dahlgren, K. N., A. M. Manelli, W. B. Stine, Jr., L. K. Baker, G. A. Krafft, and M. J. LaDu. (2002). 
Oligomeric and fibrillar species of amyloid-beta peptides differentially affect 
neuronal viability. J Biol Chem 277 (35):32046-53. 
Daitoku, H., M. Hatta, H. Matsuzaki, S. Aratani, T. Ohshima, M. Miyagishi, T. Nakajima, and 
A. Fukamizu. (2004). Silent information regulator 2 potentiates Foxo1-mediated 
transcription through its deacetylase activity. Proc Natl Acad Sci U S A 101 (27):10042-
7. 
www.intechopen.com
Role of Central Insulin-Like Growth Factor-1  
Receptor Signalling in Ageing and Endocrine Regulation 
 
239 
de la Torre-Ubieta, L., B. Gaudilliere, Y. Yang, Y. Ikeuchi, T. Yamada, S. DiBacco, J. Stegmuller, 
U. Schuller, D. A. Salih, D. Rowitch, A. Brunet, and A. Bonni. (2010). A FOXO-Pak1 
transcriptional pathway controls neuronal polarity. Genes Dev 24 (8):799-813. 
De Strooper, B. (2003). Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-
Secretase complex. Neuron 38 (1):9-12. 
Deitel, K., D. Dantzer, P. Ferguson, M. Pollak, W. Beamer, I. Andrulis, and R. Bell. (2002). 
Reduced growth of human sarcoma xenografts in hosts homozygous for the lit 
mutation. J Surg Oncol 81 (2):75-9. 
Dijkers, P. F., R. H. Medema, J. W. Lammers, L. Koenderman, and P. J. Coffer. (2000). 
Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the 
forkhead transcription factor FKHR-L1. Curr Biol 10 (19):1201-4. 
Dijkers, P. F., R. H. Medema, C. Pals, L. Banerji, N. S. Thomas, E. W. Lam, B. M. Burgering, J. 
A. Raaijmakers, J. W. Lammers, L. Koenderman, and P. J. Coffer. (2000). Forkhead 
transcription factor FKHR-L1 modulates cytokine-dependent transcriptional 
regulation of p27(KIP1). Mol Cell Biol 20 (24):9138-48. 
Dong, M. Q., J. D. Venable, N. Au, T. Xu, S. K. Park, D. Cociorva, J. R. Johnson, A. Dillin, and J. 
R. Yates, 3rd. (2007). Quantitative mass spectrometry identifies insulin signaling 
targets in C. elegans. Science 317 (5838):660-3. 
Dore, S., S. Kar, and R. Quirion. (1997). Presence and differential internalization of two distinct 
insulin-like growth factor receptors in rat hippocampal neurons. Neuroscience 78 
(2):373-83. 
Duan, C., and Q. Xu. (2005). Roles of insulin-like growth factor (IGF) binding proteins in 
regulating IGF actions. Gen Comp Endocrinol 142 (1-2):44-52. 
Duffy, K. R., W. M. Pardridge, and R. G. Rosenfeld. (1988). Human blood-brain barrier insulin-
like growth factor receptor. Metabolism 37 (2):136-40. 
Edwards, D. C., L. C. Sanders, G. M. Bokoch, and G. N. Gill. (1999). Activation of LIM-kinase 
by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat 
Cell Biol 1 (5):253-9. 
Essers, M. A., S. Weijzen, A. M. de Vries-Smits, I. Saarloos, N. D. de Ruiter, J. L. Bos, and B. M. 
Burgering. (2004). FOXO transcription factor activation by oxidative stress mediated 
by the small GTPase Ral and JNK. EMBO J 23 (24):4802-12. 
Firth, S. M., and R. C. Baxter. (2002). Cellular actions of the insulin-like growth factor binding 
proteins. Endocr Rev 23 (6):824-54. 
Flachsbart, F., A. Caliebe, R. Kleindorp, H. Blanche, H. von Eller-Eberstein, S. Nikolaus, S. 
Schreiber, and A. Nebel. (2009). Association of FOXO3A variation with human 
longevity confirmed in German centenarians. Proc Natl Acad Sci U S A 106 (8):2700-5. 
Flaherty, D. B., J. P. Soria, H. G. Tomasiewicz, and J. G. Wood. (2000). Phosphorylation of 
human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key 
participants. J Neurosci Res 62 (3):463-72. 
Flurkey, K., J. Papaconstantinou, R. A. Miller, and D. E. Harrison. (2001). Lifespan extension 
and delayed immune and collagen aging in mutant mice with defects in growth 
hormone production. Proc Natl Acad Sci U S A 98 (12):6736-41. 
Fowlkes, J. L., K. M. Thrailkill, D. M. Serra, K. Suzuki, and H. Nagase. (1995). Matrix 
metalloproteinases as insulin-like growth factor binding protein-degrading 
proteinases. Prog Growth Factor Res 6 (2-4):255-63. 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
240 
Francis, G. L., F. M. Upton, F. J. Ballard, K. A. McNeil, and J. C. Wallace. (1988). Insulin-like 
growth factors 1 and 2 in bovine colostrum. Sequences and biological activities 
compared with those of a potent truncated form. Biochem J 251 (1):95-103. 
Frasca, F., G. Pandini, P. Scalia, L. Sciacca, R. Mineo, A. Costantino, I. D. Goldfine, A. Belfiore, 
and R. Vigneri. (1999). Insulin receptor isoform A, a newly recognized, high-affinity 
insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19 (5):3278-
88. 
Fratiglioni, L., S. Paillard-Borg, and B. Winblad. (2004). An active and socially integrated 
lifestyle in late life might protect against dementia. Lancet Neurol 3 (6):343-53. 
Freude, S., M. M. Hettich, C. Schumann, O. Stohr, L. Koch, C. Kohler, M. Udelhoven, U. 
Leeser, M. Muller, N. Kubota, T. Kadowaki, W. Krone, H. Schroder, J. C. Bruning, and 
M. Schubert. (2009). Neuronal IGF-1 resistance reduces Abeta accumulation and 
protects against premature death in a model of Alzheimer's disease. FASEB J 23 
(10):3315-24. 
Freude, S., K. Schilbach, and M. Schubert. (2009). The role of IGF-1 receptor and insulin 
receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms 
to human disease. Curr Alzheimer Res 6 (3):213-23. 
Frohman, L. A., and J. O. Jansson. (1986). Growth hormone-releasing hormone. Endocr Rev 7 
(3):223-53. 
Frolich, L., D. Blum-Degen, H. G. Bernstein, S. Engelsberger, J. Humrich, S. Laufer, D. 
Muschner, A. Thalheimer, A. Turk, S. Hoyer, R. Zochling, K. W. Boissl, K. Jellinger, 
and P. Riederer. (1998). Brain insulin and insulin receptors in aging and sporadic 
Alzheimer's disease. J Neural Transm 105 (4-5):423-38. 
Frolich, L., D. Blum-Degen, P. Riederer, and S. Hoyer. (1999). A disturbance in the neuronal 
insulin receptor signal transduction in sporadic Alzheimer's disease. Ann N Y Acad 
Sci 893:290-3. 
Fruman, D. A., R. E. Meyers, and L. C. Cantley. (1998). Phosphoinositide kinases. Annu Rev 
Biochem 67:481-507. 
Fruman, D.A., L.E. Rameh, and L.C. Cantley. (1999). Phosphoinositide binding domains: 
Embracing 3-phosphate. Cell. 97(7):817-820 
Furuyama, T., T. Nakazawa, I. Nakano, and N. Mori. (2000). Identification of the differential 
distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 
homologues. Biochem J 349 (Pt 2):629-34. 
Gage, P. J., M. L. Roller, T. L. Saunders, L. M. Scarlett, and S. A. Camper. (1996). Anterior 
pituitary cells defective in the cell-autonomous factor, df, undergo cell lineage 
specification but not expansion. Development 122 (1):151-60. 
Garcia-Segura, L. M., J. Perez, S. Pons, M. T. Rejas, and I. Torres-Aleman. (1991). Localization 
of insulin-like growth factor I (IGF-I)-like immunoreactivity in the developing and 
adult rat brain. Brain Res 560 (1-2):167-74. 
Georganopoulou, D. G., L. Chang, J. M. Nam, C. S. Thaxton, E. J. Mufson, W. L. Klein, and C. 
A. Mirkin. (2005). Nanoparticle-based detection in cerebral spinal fluid of a soluble 
pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 102 (7):2273-6. 
Ghahary, A., E. E. Tredget, Q. Shen, R. T. Kilani, P. G. Scott, and Y. Houle. (2000). Mannose-6-
phosphate/IGF-II receptors mediate the effects of IGF-1-induced latent transforming 
growth factor beta 1 on expression of type I collagen and collagenase in dermal 
fibroblasts. Growth Factors 17 (3):167-76. 
www.intechopen.com
Role of Central Insulin-Like Growth Factor-1  
Receptor Signalling in Ageing and Endocrine Regulation 
 
241 
Giovannone, B., M.L. Scaldaferri, M. Federici, O. Porzio, D. Lauro, A. Fusco, P. Sbraccia, P. 
Borboni, R. Lauro and G. Sesti. Insulin receptor substrate (IRS) transduction system: 
distinct and overlapping signaling potential. (2000). Diabetes Metab Res Rev. 16(6):434-
441. 
Giustina, A., and J. D. Veldhuis. (1998). Pathophysiology of the neuroregulation of growth 
hormone secretion in experimental animals and the human. Endocr Rev 19 (6):717-97. 
Goedert, M., and M. G. Spillantini. (2006). A century of Alzheimer's disease. Science 314 
(5800):777-81. 
Goldberg, J. L. (2004). Intrinsic neuronal regulation of axon and dendrite growth. Curr Opin 
Neurobiol 14 (5):551-7. 
Goldgaber, D., M. I. Lerman, O. W. McBride, U. Saffiotti, and D. C. Gajdusek. (1987). 
Characterization and chromosomal localization of a cDNA encoding brain amyloid of 
Alzheimer's disease. Science 235 (4791):877-80. 
Goldstein, B. J., and C. R. Kahn. (1989). Analysis of mRNA heterogeneity by ribonuclease H 
mapping: application to the insulin receptor. Biochem Biophys Res Commun 159 (2):664-
9. 
Gotz, J., L. M. Ittner, and S. Kins. (2006). Do axonal defects in tau and amyloid precursor 
protein transgenic animals model axonopathy in Alzheimer's disease? J Neurochem 98 
(4):993-1006. 
Gual, P., T. Gremeaux, T. Gonzalez, Y. Le Marchand-Brustel, and J. F. Tanti. (2003). MAP 
kinases and mTOR mediate insulin-induced phosphorylation of insulin receptor 
substrate-1 on serine residues 307, 612 and 632. Diabetologia 46 (11):1532-42. 
Gual, P., Y. Le Marchand-Brustel, and J. F. Tanti. (2005). Positive and negative regulation of 
insulin signaling through IRS-1 phosphorylation. Biochimie 87 (1):99-109. 
Guan, J., H. J. Waldvogel, R. L. Faull, P. D. Gluckman, and C. E. Williams. (1999). The effects of 
the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate in 
different regions following hypoxic-ischemic brain injury in adult rats. Neuroscience 
89 (3):649-59. 
Guevara-Aguirre, J., P. Balasubramanian, M. Guevara-Aguirre, M. Wei, F. Madia, C. W. 
Cheng, D. Hwang, A. Martin-Montalvo, J. Saavedra, S. Ingles, R. de Cabo, P. Cohen, 
and V. D. Longo. (2011). Growth hormone receptor deficiency is associated with a 
major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl 
Med 3 (70):70ra13. 
Guillozet-Bongaarts, A. L., M. E. Cahill, V. L. Cryns, M. R. Reynolds, R. W. Berry, and L. I. 
Binder. (2006). Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: 
in vitro evidence and implications for tangle formation in vivo. J Neurochem 97 
(4):1005-14. 
Haass, C., and D. J. Selkoe. (2007). Soluble protein oligomers in neurodegeneration: lessons 
from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8 (2):101-12. 
Hanger, D. P., K. Hughes, J. R. Woodgett, J. P. Brion, and B. H. Anderton. (1992). Glycogen 
synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: 
generation of paired helical filament epitopes and neuronal localisation of the kinase. 
Neurosci Lett 147 (1):58-62. 
Harada, H., B. Becknell, M. Wilm, M. Mann, L. J. Huang, S. S. Taylor, J. D. Scott, and S. J. 
Korsmeyer. (1999). Phosphorylation and inactivation of BAD by mitochondria-
anchored protein kinase A. Mol Cell 3 (4):413-22. 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
242 
Hardy, J., and D. J. Selkoe. (2002). The amyloid hypothesis of Alzheimer's disease: progress 
and problems on the road to therapeutics. Science 297 (5580):353-6. 
Harper, J. D., and P. T. Lansbury, Jr. (1997). Models of amyloid seeding in Alzheimer's disease 
and scrapie: mechanistic truths and physiological consequences of the time-
dependent solubility of amyloid proteins. Annu Rev Biochem 66:385-407. 
Harper, J. D., S. S. Wong, C. M. Lieber, and P. T. Lansbury, Jr. (1999). Assembly of A beta 
amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's 
disease. Biochemistry 38 (28):8972-80. 
Harrington, S. C., R. D. Simari, and C. A. Conover. (2007). Genetic deletion of pregnancy-
associated plasma protein-A is associated with resistance to atherosclerotic lesion 
development in apolipoprotein E-deficient mice challenged with a high-fat diet. Circ 
Res 100 (12):1696-702. 
Hauck, S. J., J. M. Aaron, C. Wright, J. J. Kopchick, and A. Bartke. (2002). Antioxidant enzymes, 
free-radical damage, and response to paraquat in liver and kidney of long-living 
growth hormone receptor/binding protein gene-disrupted mice. Horm Metab Res 34 
(9):481-6. 
Hauck, S. J., W. S. Hunter, N. Danilovich, J. J. Kopchick, and A. Bartke. (2001). Reduced levels 
of thyroid hormones, insulin, and glucose, and lower body core temperature in the 
growth hormone receptor/binding protein knockout mouse. Exp Biol Med (Maywood) 
226 (6):552-8. 
Hawkes, C., and S. Kar. (2004). The insulin-like growth factor-II/mannose-6-phosphate 
receptor: structure, distribution and function in the central nervous system. Brain Res 
Brain Res Rev 44 (2-3):117-40. 
Hayashi, M. L., S. Y. Choi, B. S. Rao, H. Y. Jung, H. K. Lee, D. Zhang, S. Chattarji, A. Kirkwood, 
and S. Tonegawa. (2004). Altered cortical synaptic morphology and impaired 
memory consolidation in forebrain- specific dominant-negative PAK transgenic mice. 
Neuron 42 (5):773-87. 
Hayashi, M. L., B. S. Rao, J. S. Seo, H. S. Choi, B. M. Dolan, S. Y. Choi, S. Chattarji, and S. 
Tonegawa. (2007). Inhibition of p21-activated kinase rescues symptoms of fragile X 
syndrome in mice. Proc Natl Acad Sci U S A 104 (27):11489-94. 
Herschkovitz, A., Y. F. Liu, E. Ilan, D. Ronen, S. Boura-Halfon, and Y. Zick. (2007). Common 
inhibitory serine sites phosphorylated by IRS-1 kinases, triggered by insulin and 
inducers of insulin resistance. J Biol Chem 282 (25):18018-27. 
Hirokawa, N., T. Funakoshi, R. Sato-Harada, and Y. Kanai. (1996). Selective stabilization of tau 
in axons and microtubule-associated protein 2C in cell bodies and dendrites 
contributes to polarized localization of cytoskeletal proteins in mature neurons. J Cell 
Biol 132 (4):667-79. 
Ho, L., W. Qin, P. N. Pompl, Z. Xiang, J. Wang, Z. Zhao, Y. Peng, G. Cambareri, A. Rocher, C. 
V. Mobbs, P. R. Hof, and G. M. Pasinetti. (2004). Diet-induced insulin resistance 
promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 
18 (7):902-4. 
Hoeflich, A., R. Reisinger, B. S. Schuett, M. W. Elmlinger, V. C. Russo, G. A. Vargas, P. M. 
Jehle, H. Lahm, I. Renner-Muller, and E. Wolf. (2004). Peri/nuclear localization of 
intact insulin-like growth factor binding protein-2 and a distinct carboxyl-terminal 
IGFBP-2 fragment in vivo. Biochem Biophys Res Commun 324 (2):705-10. 
www.intechopen.com
Role of Central Insulin-Like Growth Factor-1  
Receptor Signalling in Ageing and Endocrine Regulation 
 
243 
Hoekman, M. F., F. M. Jacobs, M. P. Smidt, and J. P. Burbach. (2006). Spatial and temporal 
expression of FoxO transcription factors in the developing and adult murine brain. 
Gene Expr Patterns 6 (2):134-40. 
Holzenberger, M., J. Dupont, B. Ducos, P. Leneuve, A. Geloen, P. C. Even, P. Cervera, and Y. 
Le Bouc. (2003). IGF-1 receptor regulates lifespan and resistance to oxidative stress in 
mice. Nature 421 (6919):182-7. 
Holzenberger, M., G. Hamard, R. Zaoui, P. Leneuve, B. Ducos, C. Beccavin, L. Perin, and Y. Le 
Bouc. (2001). Experimental IGF-I receptor deficiency generates a sexually dimorphic 
pattern of organ-specific growth deficits in mice, affecting fat tissue in particular. 
Endocrinology 142 (10):4469-78. 
Hresko, R. C., H. Murata, and M. Mueckler. (2003). Phosphoinositide-dependent kinase-2 is a 
distinct protein kinase enriched in a novel cytoskeletal fraction associated with 
adipocyte plasma membranes. J Biol Chem 278 (24):21615-22. 
Hsu, A. L., C. T. Murphy, and C. Kenyon. (2003). Regulation of aging and age-related disease 
by DAF-16 and heat-shock factor. Science 300 (5622):1142-5. 
Huang, H., K. M. Regan, F. Wang, D. Wang, D. I. Smith, J. M. van Deursen, and D. J. Tindall. 
(2005). Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated 
degradation. Proc Natl Acad Sci U S A 102 (5):1649-54. 
Huang, H., and D. J. Tindall. (2007). Dynamic FoxO transcription factors. J Cell Sci 120 (Pt 
15):2479-87. 
Hunter, W. S., W. B. Croson, A. Bartke, M. V. Gentry, and C. J. Meliska. (1999). Low body 
temperature in long-lived Ames dwarf mice at rest and during stress. Physiol Behav 67 
(3):433-7. 
Hwangbo, D. S., B. Gershman, M. P. Tu, M. Palmer, and M. Tatar. (2004). Drosophila dFOXO 
controls lifespan and regulates insulin signalling in brain and fat body. Nature 429 
(6991):562-6. 
Ikeno, Y., R. T. Bronson, G. B. Hubbard, S. Lee, and A. Bartke. (2003). Delayed occurrence of 
fatal neoplastic diseases in ames dwarf mice: correlation to extended longevity. J 
Gerontol A Biol Sci Med Sci 58 (4):291-6. 
Ikeya, T., M. Galic, P. Belawat, K. Nairz, and E. Hafen. (2002). Nutrient-dependent expression 
of insulin-like peptides from neuroendocrine cells in the CNS contributes to growth 
regulation in Drosophila. Curr Biol 12 (15):1293-300. 
Iser, W. B., M. S. Gami, and C. A. Wolkow. (2007). Insulin signaling in Caenorhabditis elegans 
regulates both endocrine-like and cell-autonomous outputs. Dev Biol 303 (2):434-47. 
Isgaard, J., L. Carlsson, O. G. Isaksson, and J. O. Jansson. (1988). Pulsatile intravenous growth 
hormone (GH) infusion to hypophysectomized rats increases insulin-like growth 
factor I messenger ribonucleic acid in skeletal tissues more effectively than 
continuous GH infusion. Endocrinology 123 (6):2605-10. 
Ittner, L. M., Y. D. Ke, F. Delerue, M. Bi, A. Gladbach, J. van Eersel, H. Wolfing, B. C. Chieng, 
M. J. Christie, I. A. Napier, A. Eckert, M. Staufenbiel, E. Hardeman, and J. Gotz. 
(2010). Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's 
disease mouse models. Cell 142 (3):387-97. 
Iwatsubo, T., A. Odaka, N. Suzuki, H. Mizusawa, N. Nukina, and Y. Ihara. (1994). 
Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta 
monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13 
(1):45-53. 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
244 
Jacobs, F. M., L. P. van der Heide, P. J. Wijchers, J. P. Burbach, M. F. Hoekman, and M. P. 
Smidt. (2003). FoxO6, a novel member of the FoxO class of transcription factors with 
distinct shuttling dynamics. J Biol Chem 278 (38):35959-67. 
Jacobs, S., F. C. Kull, Jr., H. S. Earp, M. E. Svoboda, J. J. Van Wyk, and P. Cuatrecasas. (1983). 
Somatomedin-C stimulates the phosphorylation of the beta-subunit of its own 
receptor. J Biol Chem 258 (16):9581-4. 
Jaffe, C. A., B. Ocampo-Lim, W. Guo, K. Krueger, I. Sugahara, R. DeMott-Friberg, M. Bermann, 
and A. L. Barkan. (1998). Regulatory mechanisms of growth hormone secretion are 
sexually dimorphic. J Clin Invest 102 (1):153-64. 
Jan, Y. N., and L. Y. Jan. (2003). The control of dendrite development. Neuron 40 (2):229-42. 
Janson, J., T. Laedtke, J. E. Parisi, P. O'Brien, R. C. Petersen, and P. C. Butler. (2004). Increased 
risk of type 2 diabetes in Alzheimer disease. Diabetes 53 (2):474-81. 
Jansson, J. O., S. Eden, and O. Isaksson. (1985). Sexual dimorphism in the control of growth 
hormone secretion. Endocr Rev 6 (2):128-50. 
Jessup, S. K., E. V. Dimaraki, K. V. Symons, and A. L. Barkan. (2003). Sexual dimorphism of 
growth hormone (GH) regulation in humans: endogenous GH-releasing hormone 
maintains basal GH in women but not in men. J Clin Endocrinol Metab 88 (10):4776-80. 
Jin, M. H., Y. H. Lee, J. M. Kim, H. N. Sun, E. Y. Moon, M. H. Shong, S. U. Kim, S. H. Lee, T. H. 
Lee, D. Y. Yu, and D. S. Lee. (2005). Characterization of neural cell types expressing 
peroxiredoxins in mouse brain. Neurosci Lett 381 (3):252-7. 
Jones, J. I., and D. R. Clemmons. (1995). Insulin-like growth factors and their binding proteins: 
biological actions. Endocr Rev 16 (1):3-34. 
Junger, M. A., F. Rintelen, H. Stocker, J. D. Wasserman, M. Vegh, T. Radimerski, M. E. 
Greenberg, and E. Hafen. (2003). The Drosophila forkhead transcription factor FOXO 
mediates the reduction in cell number associated with reduced insulin signaling. J 
Biol 2 (3):20. 
Kang, J., H. G. Lemaire, A. Unterbeck, J. M. Salbaum, C. L. Masters, K. H. Grzeschik, G. 
Multhaup, K. Beyreuther, and B. Muller-Hill. (1987). The precursor of Alzheimer's 
disease amyloid A4 protein resembles a cell-surface receptor. Nature 325 (6106):733-6. 
Kang, J., and B. Muller-Hill. (1990). Differential splicing of Alzheimer's disease amyloid A4 
precursor RNA in rat tissues: PreA4(695) mRNA is predominantly produced in rat 
and human brain. Biochem Biophys Res Commun 166 (3):1192-200. 
Kappeler, L., C. De Magalhaes Filho, J. Dupont, P. Leneuve, P. Cervera, L. Perin, C. Loudes, A. 
Blaise, R. Klein, J. Epelbaum, Y. Le Bouc, and M. Holzenberger. (2008). Brain IGF-1 
receptors control mammalian growth and lifespan through a neuroendocrine 
mechanism. PLoS Biol 6 (10):e254. 
Kasuga, M., F. A. Karlsson, and C. R. Kahn. (1982). Insulin stimulates the phosphorylation of 
the 95,000-dalton subunit of its own receptor. Science 215 (4529):185-7. 
Kasuga, M., Y. Zick, D. L. Blithe, M. Crettaz, and C. R. Kahn. (1982). Insulin stimulates tyrosine 
phosphorylation of the insulin receptor in a cell-free system. Nature 298 (5875):667-9. 
Kelley, K. M., Y. Oh, S. E. Gargosky, Z. Gucev, T. Matsumoto, V. Hwa, L. Ng, D. M. Simpson, 
and R. G. Rosenfeld. (1996). Insulin-like growth factor-binding proteins (IGFBPs) and 
their regulatory dynamics. Int J Biochem Cell Biol 28 (6):619-37. 
Kenyon, C. (2005). The plasticity of aging: insights from long-lived mutants. Cell 120 (4):449-60. 
Kenyon, C., J. Chang, E. Gensch, A. Rudner, and R. Tabtiang. (1993). A C. elegans mutant that 
lives twice as long as wild type. Nature 366 (6454):461-4. 
www.intechopen.com
Role of Central Insulin-Like Growth Factor-1  
Receptor Signalling in Ageing and Endocrine Regulation 
 
245 
Kenyon, C. J. (2010). The genetics of ageing. Nature 464 (7288):504-12. 
Khan, A. S., C. D. Lynch, D. C. Sane, M. C. Willingham, and W. E. Sonntag. (2001). Growth 
hormone increases regional coronary blood flow and capillary density in aged rats. J 
Gerontol A Biol Sci Med Sci 56 (8):B364-71. 
Kheterpal, I., H. A. Lashuel, D. M. Hartley, T. Walz, P. T. Lansbury, Jr., and R. Wetzel. (2003). 
Abeta protofibrils possess a stable core structure resistant to hydrogen exchange. 
Biochemistry 42 (48):14092-8. 
Kiess, W., Y. Yang, U. Kessler, and A. Hoeflich. (1994). Insulin-like growth factor II (IGF-II) and 
the IGF-II/mannose-6-phosphate receptor: the myth continues. Horm Res 41 Suppl 
2:66-73. 
Killick, R., G. Scales, K. Leroy, M. Causevic, C. Hooper, E. E. Irvine, A. I. Choudhury, L. 
Drinkwater, F. Kerr, H. Al-Qassab, J. Stephenson, Z. Yilmaz, K. P. Giese, J. P. Brion, D. 
J. Withers, and S. Lovestone. (2009). Deletion of Irs2 reduces amyloid deposition and 
rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun 386 
(1):257-62. 
Kim, H. S., S. R. Nagalla, Y. Oh, E. Wilson, C. T. Roberts, Jr., and R. G. Rosenfeld. (1997). 
Identification of a family of low-affinity insulin-like growth factor binding proteins 
(IGFBPs): characterization of connective tissue growth factor as a member of the 
IGFBP superfamily. Proc Natl Acad Sci U S A 94 (24):12981-6. 
Kinney, B. A., K. T. Coschigano, J. J. Kopchick, R. W. Steger, and A. Bartke. (2001). Evidence 
that age-induced decline in memory retention is delayed in growth hormone resistant 
GH-R-KO (Laron) mice. Physiol Behav 72 (5):653-60. 
Kitamura, Y. I., T. Kitamura, J. P. Kruse, J. C. Raum, R. Stein, W. Gu, and D. Accili. (2005). 
FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA 
induction. Cell Metab 2 (3):153-63. 
Klein, W. L., W. B. Stine, Jr., and D. B. Teplow. (2004). Small assemblies of unmodified amyloid 
beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25 
(5):569-80. 
Kops, G. J., T. B. Dansen, P. E. Polderman, I. Saarloos, K. W. Wirtz, P. J. Coffer, T. T. Huang, J. 
L. Bos, R. H. Medema, and B. M. Burgering. (2002). Forkhead transcription factor 
FOXO3a protects quiescent cells from oxidative stress. Nature 419 (6904):316-21. 
Kops, G. J., N. D. de Ruiter, A. M. De Vries-Smits, D. R. Powell, J. L. Bos, and B. M. Burgering. 
(1999). Direct control of the Forkhead transcription factor AFX by protein kinase B. 
Nature 398 (6728):630-4. 
Kuningas, M., R. Magi, R. G. Westendorp, P. E. Slagboom, M. Remm, and D. van Heemst. 
(2007). Haplotypes in the human Foxo1a and Foxo3a genes; impact on disease and 
mortality at old age. Eur J Hum Genet 15 (3):294-301. 
Lambert, M. P., A. K. Barlow, B. A. Chromy, C. Edwards, R. Freed, M. Liosatos, T. E. Morgan, 
I. Rozovsky, B. Trommer, K. L. Viola, P. Wals, C. Zhang, C. E. Finch, G. A. Krafft, and 
W. L. Klein. (1998). Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent 
central nervous system neurotoxins. Proc Natl Acad Sci U S A 95 (11):6448-53. 
Lanz, T. A., C. T. Salatto, A. R. Semproni, M. Marconi, T. M. Brown, K. E. Richter, K. Schmidt, 
F. R. Nelson, and J. B. Schachter. (2008). Peripheral elevation of IGF-1 fails to alter 
Abeta clearance in multiple in vivo models. Biochem Pharmacol 75 (5):1093-103. 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
246 
Lavan, B. E., V. R. Fantin, E. T. Chang, W. S. Lane, S. R. Keller, and G. E. Lienhard. (1997). A 
novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a 
new member of the insulin receptor substrate family. J Biol Chem 272 (34):21403-7. 
Lavan, B. E., W. S. Lane, and G. E. Lienhard. (1997). The 60-kDa phosphotyrosine protein in 
insulin-treated adipocytes is a new member of the insulin receptor substrate family. J 
Biol Chem 272 (17):11439-43. 
Lawlor, M. A., and D. R. Alessi. (2001). PKB/Akt: a key mediator of cell proliferation, survival 
and insulin responses? J Cell Sci 114 (Pt 16):2903-10. 
Lawrence, J. B., C. Oxvig, M. T. Overgaard, L. Sottrup-Jensen, G. J. Gleich, L. G. Hays, J. R. 
Yates, 3rd, and C. A. Conover. (1999). The insulin-like growth factor (IGF)-dependent 
IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-
associated plasma protein-A. Proc Natl Acad Sci U S A 96 (6):3149-53. 
Lee, K. S., K. Iijima-Ando, K. Iijima, W. J. Lee, J. H. Lee, K. Yu, and D. S. Lee. (2009). 
JNK/FOXO-mediated neuronal expression of fly homologue of peroxiredoxin II 
reduces oxidative stress and extends life span. J Biol Chem 284 (43):29454-61. 
LeRoith, D. (2000). Insulin-like growth factor I receptor signaling--overlapping or redundant 
pathways? Endocrinology 141 (4):1287-8. 
Lesne, S., M. T. Koh, L. Kotilinek, R. Kayed, C. G. Glabe, A. Yang, M. Gallagher, and K. H. 
Ashe. (2006). A specific amyloid-beta protein assembly in the brain impairs memory. 
Nature 440 (7082):352-7. 
Leung, K. C., G. Johannsson, G. M. Leong, and K. K. Ho. (2004). Estrogen regulation of growth 
hormone action. Endocr Rev 25 (5):693-721. 
LeVine, H., 3rd. (1999). Quantification of beta-sheet amyloid fibril structures with thioflavin T. 
Methods Enzymol 309:274-84. 
Li, M., J. Luo, C. L. Brooks, and W. Gu. (2002). Acetylation of p53 inhibits its ubiquitination by 
Mdm2. J Biol Chem 277 (52):50607-11. 
Li, W., S. G. Kennedy, and G. Ruvkun. (2003). daf-28 encodes a C. elegans insulin superfamily 
member that is regulated by environmental cues and acts in the DAF-2 signaling 
pathway. Genes Dev 17 (7):844-58. 
Li, Y., Y. He, L. Qi, V. W. Jaddoe, E. J. Feskens, X. Yang, G. Ma, and F. B. Hu. (2010). Exposure 
to the Chinese famine in early life and the risk of hyperglycemia and type 2 diabetes 
in adulthood. Diabetes 59 (10):2400-6. 
Li, Y., V. W. Jaddoe, L. Qi, Y. He, D. Wang, J. Lai, J. Zhang, P. Fu, X. Yang, and F. B. Hu. (2011). 
Exposure to the Chinese Famine in Early Life and the Risk of Metabolic Syndrome in 
Adulthood. Diabetes Care. 
Li, Y., W. J. Wang, H. Cao, J. Lu, C. Wu, F. Y. Hu, J. Guo, L. Zhao, F. Yang, Y. X. Zhang, W. Li, 
G. Y. Zheng, H. Cui, X. Chen, Z. Zhu, H. He, B. Dong, X. Mo, Y. Zeng, and X. L. Tian. 
(2009). Genetic association of FOXO1A and FOXO3A with longevity trait in Han 
Chinese populations. Hum Mol Genet 18 (24):4897-904. 
Liang, H., E. J. Masoro, J. F. Nelson, R. Strong, C. A. McMahan, and A. Richardson. (2003). 
Genetic mouse models of extended lifespan. Exp Gerontol 38 (11-12):1353-64. 
Lim, Y. S., M. K. Cha, H. K. Kim, T. B. Uhm, J. W. Park, K. Kim, and I. H. Kim. (1993). 
Removals of hydrogen peroxide and hydroxyl radical by thiol-specific antioxidant 
protein as a possible role in vivo. Biochem Biophys Res Commun 192 (1):273-80. 
www.intechopen.com
Role of Central Insulin-Like Growth Factor-1  
Receptor Signalling in Ageing and Endocrine Regulation 
 
247 
Lin, K., J. B. Dorman, A. Rodan, and C. Kenyon. (1997). daf-16: An HNF-3/forkhead family 
member that can function to double the life-span of Caenorhabditis elegans. Science 
278 (5341):1319-22. 
Lin, M. T., and M. F. Beal. (2006). Mitochondrial dysfunction and oxidative stress in 
neurodegenerative diseases. Nature 443 (7113):787-95. 
Lindeboom, M., F. Portrait, and G. J. van den Berg. (2010). Long-run effects on longevity of a 
nutritional shock early in life: the Dutch Potato famine of 1846-1847. J Health Econ 29 
(5):617-29. 
Liu, J. P., J. Baker, A. S. Perkins, E. J. Robertson, and A. Efstratiadis. (1993). Mice carrying null 
mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF 
receptor (Igf1r). Cell 75 (1):59-72. 
Liu, R., X. W. Zhou, H. Tanila, C. Bjorkdahl, J. Z. Wang, Z. Z. Guan, Y. Cao, J. A. Gustafsson, B. 
Winblad, and J. J. Pei. (2008). Phosphorylated PP2A (tyrosine 307) is associated with 
Alzheimer neurofibrillary pathology. J Cell Mol Med 12 (1):241-57. 
Lopez-Lopez, C., D. LeRoith, and I. Torres-Aleman. (2004). Insulin-like growth factor I is 
required for vessel remodeling in the adult brain. Proc Natl Acad Sci U S A 101 
(26):9833-8. 
Louvi, A., D. Accili, and A. Efstratiadis. (1997). Growth-promoting interaction of IGF-II with 
the insulin receptor during mouse embryonic development. Dev Biol 189 (1):33-48. 
Luchsinger, J. A., M. X. Tang, S. Shea, and R. Mayeux. (2004). Hyperinsulinemia and risk of 
Alzheimer disease. Neurology 63 (7):1187-92. 
Luo, M., P. Langlais, Z. Yi, N. Lefort, E. A. De Filippis, H. Hwang, C. Y. Christ-Roberts, and L. 
J. Mandarino. (2007). Phosphorylation of human insulin receptor substrate-1 at Serine 
629 plays a positive role in insulin signaling. Endocrinology 148 (10):4895-905. 
Luo, M., S. Reyna, L. Wang, Z. Yi, C. Carroll, L. Q. Dong, P. Langlais, S. T. Weintraub, and L. J. 
Mandarino. (2005). Identification of insulin receptor substrate 1 serine/threonine 
phosphorylation sites using mass spectrometry analysis: regulatory role of serine 
1223. Endocrinology 146 (10):4410-6. 
Luo, Z. C., W. D. Fraser, P. Julien, C. L. Deal, F. Audibert, G. N. Smith, X. Xiong, and M. 
Walker. (2006). Tracing the origins of "fetal origins" of adult diseases: programming 
by oxidative stress? Med Hypotheses 66 (1):38-44. 
Maile, L. A., and J. M. Holly. (1999). Insulin-like growth factor binding protein (IGFBP) 
proteolysis: occurrence, identification, role and regulation. Growth Horm IGF Res 9 
(2):85-95. 
Major, J. M., G. A. Laughlin, D. Kritz-Silverstein, D. L. Wingard, and E. Barrett-Connor. (2010). 
Insulin-like growth factor-I and cancer mortality in older men. J Clin Endocrinol Metab 
95 (3):1054-9. 
Marks, J. L., D. Porte, Jr., and D. G. Baskin. (1991). Localization of type I insulin-like growth 
factor receptor messenger RNA in the adult rat brain by in situ hybridization. Mol 
Endocrinol 5 (8):1158-68. 
Masters, C. L., G. Simms, N. A. Weinman, G. Multhaup, B. L. McDonald, and K. Beyreuther. 
(1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc 
Natl Acad Sci U S A 82 (12):4245-9. 
Matsuo, K., M. Niwa, M. Kurihara, K. Shigematsu, S. Yamashita, M. Ozaki, and S. Nagataki. 
(1989). Receptor autoradiographic analysis of insulin-like growth factor-I (IGF-I) 
binding sites in rat forebrain and pituitary gland. Cell Mol Neurobiol 9 (3):357-67. 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
248 
Matthieu, J. M., S. Widmer, and N. Herschkowitz. (1973). Biochemical changes in mouse brain 
composition during myelination. Brain Res 55 (2):391-402. 
McClain, D. A. (1991). Different ligand affinities of the two human insulin receptor splice 
variants are reflected in parallel changes in sensitivity for insulin action. Mol 
Endocrinol 5 (5):734-9. 
McLean, C. A., R. A. Cherny, F. W. Fraser, S. J. Fuller, M. J. Smith, K. Beyreuther, A. I. Bush, 
and C. L. Masters. (1999). Soluble pool of Abeta amyloid as a determinant of severity 
of neurodegeneration in Alzheimer's disease. Ann Neurol 46 (6):860-6. 
McMorris, F. A., and M. Dubois-Dalcq. (1988). Insulin-like growth factor I promotes cell 
proliferation and oligodendroglial commitment in rat glial progenitor cells 
developing in vitro. J Neurosci Res 21 (2-4):199-209. 
McMorris, F. A., T. M. Smith, S. DeSalvo, and R. W. Furlanetto. (1986). Insulin-like growth 
factor I/somatomedin C: a potent inducer of oligodendrocyte development. Proc Natl 
Acad Sci U S A 83 (3):822-6. 
Medema, R. H., G. J. Kops, J. L. Bos, and B. M. Burgering. (2000). AFX-like Forkhead 
transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. 
Nature 404 (6779):782-7. 
Michaluk, P., and L. Kaczmarek. (2007). Matrix metalloproteinase-9 in glutamate-dependent 
adult brain function and dysfunction. Cell Death Differ 14 (7):1255-8. 
Miller, R. A., J. M. Harper, A. Galecki, and D. T. Burke. (2002). Big mice die young: early life 
body weight predicts longevity in genetically heterogeneous mice. Aging Cell 1 (1):22-
9. 
Millward, T. A., S. Zolnierowicz, and B. A. Hemmings. (1999). Regulation of protein kinase 
cascades by protein phosphatase 2A. Trends Biochem Sci 24 (5):186-91. 
Mohan, S., and D. J. Baylink. (2002). IGF-binding proteins are multifunctional and act via IGF-
dependent and -independent mechanisms. J Endocrinol 175 (1):19-31. 
Mohseni-Zadeh, S., and M. Binoux. (1997). Insulin-like growth factor (IGF) binding protein-3 
interacts with the type 1 IGF receptor, reducing the affinity of the receptor for its 
ligand: an alternative mechanism in the regulation of IGF action. Endocrinology 138 
(12):5645-8. 
Moller, D. E., A. Yokota, J. F. Caro, and J. S. Flier. (1989). Tissue-specific expression of two 
alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol 3 (8):1263-9. 
Moloney, A. M., R. J. Griffin, S. Timmons, R. O'Connor, R. Ravid, and C. O'Neill. (2010). 
Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease 
indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31 (2):224-
43. 
Morell, P., S. Greenfield, E. Costantino-Ceccarini, and H. Wisniewski. (1972). Changes in the 
protein composition of mouse brain myelin during development. J Neurochem 19 
(11):2545-54. 
Morgan, D. O., J. C. Edman, D. N. Standring, V. A. Fried, M. C. Smith, R. A. Roth, and W. J. 
Rutter. (1987). Insulin-like growth factor II receptor as a multifunctional binding 
protein. Nature 329 (6137):301-7. 
Morris, J. Z., H. A. Tissenbaum, and G. Ruvkun. (1996). A phosphatidylinositol-3-OH kinase 
family member regulating longevity and diapause in Caenorhabditis elegans. Nature 
382 (6591):536-9. 
www.intechopen.com
Role of Central Insulin-Like Growth Factor-1  
Receptor Signalling in Ageing and Endocrine Regulation 
 
249 
Moxham, C. P., V. Duronio, and S. Jacobs. (1989). Insulin-like growth factor I receptor beta-
subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like 
growth factor I and insulin receptor heterodimers. J Biol Chem 264 (22):13238-44. 
Mozell, R. L., and F. A. McMorris. (1991). Insulin-like growth factor I stimulates 
oligodendrocyte development and myelination in rat brain aggregate cultures. J 
Neurosci Res 30 (2):382-90. 
Muller-Hill, B., and K. Beyreuther. (1989). Molecular biology of Alzheimer's disease. Annu Rev 
Biochem 58:287-307. 
Mullis, P. E. (2005). Genetic control of growth. Eur J Endocrinol 152 (1):11-31. 
Murakami, S. (2007). Caenorhabditis elegans as a model system to study aging of learning and 
memory. Mol Neurobiol 35 (1):85-94. 
Murakami, S., A. Salmon, and R. A. Miller. (2003). Multiplex stress resistance in cells from 
long-lived dwarf mice. FASEB J 17 (11):1565-6. 
Nakagawa, T., H. Zhu, N. Morishima, E. Li, J. Xu, B. A. Yankner, and J. Yuan. (2000). Caspase-
12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-
beta. Nature 403 (6765):98-103. 
Nikolic, M. (2008). The Pak1 kinase: an important regulator of neuronal morphology and 
function in the developing forebrain. Mol Neurobiol 37 (2-3):187-202. 
Nishijima, T., J. Piriz, S. Duflot, A. M. Fernandez, G. Gaitan, U. Gomez-Pinedo, J. M. Verdugo, 
F. Leroy, H. Soya, A. Nunez, and I. Torres-Aleman. (2010). Neuronal activity drives 
localized blood-brain-barrier transport of serum insulin-like growth factor-I into the 
CNS. Neuron 67 (5):834-46. 
Nojima, H., C. Tokunaga, S. Eguchi, N. Oshiro, S. Hidayat, K. Yoshino, K. Hara, N. Tanaka, J. 
Avruch, and K. Yonezawa. (2003). The mammalian target of rapamycin (mTOR) 
partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their 
TOR signaling (TOS) motif. J Biol Chem 278 (18):15461-4. 
Ogasawara, M., K. P. Karey, H. Marquardt, and D. A. Sirbasku. (1989). Identification and 
purification of truncated insulin-like growth factor I from porcine uterus. Evidence 
for high biological potency. Biochemistry 28 (6):2710-21. 
Ogg, S., S. Paradis, S. Gottlieb, G. I. Patterson, L. Lee, H. A. Tissenbaum, and G. Ruvkun. 
(1997). The Fork head transcription factor DAF-16 transduces insulin-like metabolic 
and longevity signals in C. elegans. Nature 389 (6654):994-9. 
Oh, Y., M. W. Beukers, H. M. Pham, P. A. Smanik, M. C. Smith, and R. G. Rosenfeld. (1991). 
Altered affinity of insulin-like growth factor II (IGF-II) for receptors and IGF-binding 
proteins, resulting from limited modifications of the IGF-II molecule. Biochem J 278 ( 
Pt 1):249-54. 
Oh, Y., H. L. Muller, G. Lamson, and R. G. Rosenfeld. (1993). Insulin-like growth factor (IGF)-
independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. 
Cell surface binding and growth inhibition. J Biol Chem 268 (20):14964-71. 
Ohlsson, C., S. Mohan, K. Sjogren, A. Tivesten, J. Isgaard, O. Isaksson, J. O. Jansson, and J. 
Svensson. (2009). The role of liver-derived insulin-like growth factor-I. Endocr Rev 30 
(5):494-535. 
Orme, S. M., R. J. McNally, R. A. Cartwright, and P. E. Belchetz. (1998). Mortality and cancer 
incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly 
Study Group. J Clin Endocrinol Metab 83 (8):2730-4. 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
250 
Oshiro, N., K. Yoshino, S. Hidayat, C. Tokunaga, K. Hara, S. Eguchi, J. Avruch, and K. 
Yonezawa. (2004). Dissociation of raptor from mTOR is a mechanism of rapamycin-
induced inhibition of mTOR function. Genes Cells 9 (4):359-66. 
Ott, A., R. P. Stolk, A. Hofman, F. van Harskamp, D. E. Grobbee, and M. M. Breteler. (1996). 
Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 39 
(11):1392-7. 
Ott, A., R. P. Stolk, F. van Harskamp, H. A. Pols, A. Hofman, and M. M. Breteler. (1999). 
Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53 
(9):1937-42. 
Ott, A., C. T. van Rossum, F. van Harskamp, H. van de Mheen, A. Hofman, and M. M. 
Breteler. (1999). Education and the incidence of dementia in a large population-based 
study: the Rotterdam Study. Neurology 52 (3):663-6. 
P, E. Mullis. (2010). Genetics of isolated growth hormone deficiency. J Clin Res Pediatr 
Endocrinol 2 (2):52-62. 
Painter, R. C., T. J. Roseboom, and O. P. Bleker. (2005). Prenatal exposure to the Dutch famine 
and disease in later life: an overview. Reprod Toxicol 20 (3):345-52. 
Pan, W., and A. J. Kastin. (2000). Interactions of IGF-1 with the blood-brain barrier in vivo and 
in situ. Neuroendocrinology 72 (3):171-8. 
Pandini, G., F. Frasca, R. Mineo, L. Sciacca, R. Vigneri, and A. Belfiore. (2002). Insulin/insulin-
like growth factor I hybrid receptors have different biological characteristics 
depending on the insulin receptor isoform involved. J Biol Chem 277 (42):39684-95. 
Paradis, S., and G. Ruvkun. (1998). Caenorhabditis elegans Akt/PKB transduces insulin 
receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor. Genes 
Dev 12 (16):2488-98. 
Partridge, L., and J. C. Bruning. (2008). Forkhead transcription factors and ageing. Oncogene 27 
(16):2351-63. 
Pawlikowska, L., D. Hu, S. Huntsman, A. Sung, C. Chu, J. Chen, A. H. Joyner, N. J. Schork, W. 
C. Hsueh, A. P. Reiner, B. M. Psaty, G. Atzmon, N. Barzilai, S. R. Cummings, W. S. 
Browner, P. Y. Kwok, and E. Ziv. (2009). Association of common genetic variation in 
the insulin/IGF1 signaling pathway with human longevity. Aging Cell 8 (4):460-72. 
Pierce, S. B., M. Costa, R. Wisotzkey, S. Devadhar, S. A. Homburger, A. R. Buchman, K. C. 
Ferguson, J. Heller, D. M. Platt, A. A. Pasquinelli, L. X. Liu, S. K. Doberstein, and G. 
Ruvkun. (2001). Regulation of DAF-2 receptor signaling by human insulin and ins-1, 
a member of the unusually large and diverse C. elegans insulin gene family. Genes 
Dev 15 (6):672-86. 
Pilcher, H. (2006). Alzheimer's disease could be "type 3 diabetes". Lancet Neurol 5 (5):388-9. 
Piper, M. D., C. Selman, J. J. McElwee, and L. Partridge. (2008). Separating cause from effect: 
how does insulin/IGF signalling control lifespan in worms, flies and mice? J Intern 
Med 263 (2):179-91. 
Pollak, M. N., E. S. Schernhammer, and S. E. Hankinson. (2004). Insulin-like growth factors 
and neoplasia. Nat Rev Cancer 4 (7):505-18. 
Polleux, F., G. Ince-Dunn, and A. Ghosh. (2007). Transcriptional regulation of vertebrate axon 
guidance and synapse formation. Nat Rev Neurosci 8 (5):331-40. 
Poretsky, L., N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice. (1999). The insulin-related 
ovarian regulatory system in health and disease. Endocr Rev 20 (4):535-82. 
www.intechopen.com
Role of Central Insulin-Like Growth Factor-1  
Receptor Signalling in Ageing and Endocrine Regulation 
 
251 
Puglielli, L. (2008). Aging of the brain, neurotrophin signaling, and Alzheimer's disease: is 
IGF1-R the common culprit? Neurobiol Aging 29 (6):795-811. 
Puglielli, L., B. C. Ellis, A. J. Saunders, and D. M. Kovacs. (2003). Ceramide stabilizes beta-site 
amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide 
biogenesis. J Biol Chem 278 (22):19777-83. 
Puig, O., M. T. Marr, M. L. Ruhf, and R. Tjian. (2003). Control of cell number by Drosophila 
FOXO: downstream and feedback regulation of the insulin receptor pathway. Genes 
Dev 17 (16):2006-20. 
Qin, X., D. D. Strong, D. J. Baylink, and S. Mohan. (1998). Structure-function analysis of the 
human insulin-like growth factor binding protein-4. J Biol Chem 273 (36):23509-16. 
Radulescu, R. T. (1994). Nuclear localization signal in insulin-like growth factor-binding 
protein type 3. Trends Biochem Sci 19 (7):278. 
Rajah, R., L. Katz, S. Nunn, P. Solberg, T. Beers, and P. Cohen. (1995). Insulin-like growth 
factor binding protein (IGFBP) proteases: functional regulators of cell growth. Prog 
Growth Factor Res 6 (2-4):273-84. 
Rajaram, S., D. J. Baylink, and S. Mohan. (1997). Insulin-like growth factor-binding proteins in 
serum and other biological fluids: regulation and functions. Endocr Rev 18 (6):801-31. 
Ravelli, A. C., J. H. van der Meulen, R. P. Michels, C. Osmond, D. J. Barker, C. N. Hales, and O. 
P. Bleker. (1998). Glucose tolerance in adults after prenatal exposure to famine. Lancet 
351 (9097):173-7. 
Ravelli, A. C., J. H. van Der Meulen, C. Osmond, D. J. Barker, and O. P. Bleker. (1999). Obesity 
at the age of 50 y in men and women exposed to famine prenatally. Am J Clin Nutr 70 
(5):811-6. 
Rechler, M. M. (1993). Insulin-like growth factor binding proteins. Vitam Horm 47:1-114. 
Rechler, M. M., and D. R. Clemmons. (1998). Regulatory Actions of Insulin-like Growth Factor-
binding Proteins. Trends Endocrinol Metab 9 (5):176-83. 
Rena, G., S. Guo, S. C. Cichy, T. G. Unterman, and P. Cohen. (1999). Phosphorylation of the 
transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem 
274 (24):17179-83. 
Renault, V. M., V. A. Rafalski, A. A. Morgan, D. A. Salih, J. O. Brett, A. E. Webb, S. A. Villeda, 
P. U. Thekkat, C. Guillerey, N. C. Denko, T. D. Palmer, A. J. Butte, and A. Brunet. 
(2009). FoxO3 regulates neural stem cell homeostasis. Cell Stem Cell 5 (5):527-39. 
Resch, Z. T., R. D. Simari, and C. A. Conover. (2006). Targeted disruption of the pregnancy-
associated plasma protein-A gene is associated with diminished smooth muscle cell 
response to insulin-like growth factor-I and resistance to neointimal hyperplasia after 
vascular injury. Endocrinology 147 (12):5634-40. 
Rincon, M., E. Rudin, and N. Barzilai. (2005). The insulin/IGF-1 signaling in mammals and its 
relevance to human longevity. Exp Gerontol 40 (11):873-7. 
Rivera, E. J., A. Goldin, N. Fulmer, R. Tavares, J. R. Wands, and S. M. de la Monte. (2005). 
Insulin and insulin-like growth factor expression and function deteriorate with 
progression of Alzheimer's disease: link to brain reductions in acetylcholine. J 
Alzheimers Dis 8 (3):247-68. 
Robakis, N. K., H. M. Wisniewski, E. C. Jenkins, E. A. Devine-Gage, G. E. Houck, X. L. Yao, N. 
Ramakrishna, G. Wolfe, W. P. Silverman, and W. T. Brown. (1987). Chromosome 
21q21 sublocalisation of gene encoding beta-amyloid peptide in cerebral vessels and 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
252 
neuritic (senile) plaques of people with Alzheimer disease and Down syndrome. 
Lancet 1 (8529):384-5. 
Roberson, E. D., and L. Mucke. (2006). 100 years and counting: prospects for defeating 
Alzheimer's disease. Science 314 (5800):781-4. 
Robertson, J., T. L. Loviny, M. Goedert, R. Jakes, K. J. Murray, B. H. Anderton, and D. P. 
Hanger. (1993). Phosphorylation of tau by cyclic-AMP-dependent protein kinase. 
Dementia 4 (5):256-63. 
Rogaev, E. I., R. Sherrington, E. A. Rogaeva, G. Levesque, M. Ikeda, Y. Liang, H. Chi, C. Lin, K. 
Holman, T. Tsuda, and et al. (1995). Familial Alzheimer's disease in kindreds with 
missense mutations in a gene on chromosome 1 related to the Alzheimer's disease 
type 3 gene. Nature 376 (6543):775-8. 
Roher, A. E., M. O. Chaney, Y. M. Kuo, S. D. Webster, W. B. Stine, L. J. Haverkamp, A. S. 
Woods, R. J. Cotter, J. M. Tuohy, G. A. Krafft, B. S. Bonnell, and M. R. Emmerling. 
(1996). Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and 
vascular amyloid deposits of Alzheimer's disease. J Biol Chem 271 (34):20631-5. 
Rollo, C. D. (2002). Growth negatively impacts the life span of mammals. Evol Dev 4 (1):55-61. 
Roman, G., K. Endo, L. Zong, and R. L. Davis. (2001). P[Switch], a system for spatial and 
temporal control of gene expression in Drosophila melanogaster. Proc Natl Acad Sci U 
S A 98 (22):12602-7. 
Romanick, M. A., S. G. Rakoczy, and H. M. Brown-Borg. (2004). Long-lived Ames dwarf 
mouse exhibits increased antioxidant defense in skeletal muscle. Mech Ageing Dev 125 
(4):269-81. 
Romero, C. J., Y. Ng, R. M. Luque, R. D. Kineman, L. Koch, J. C. Bruning, and S. Radovick. 
(2010). Targeted deletion of somatotroph insulin-like growth factor-I signaling in a 
cell-specific knockout mouse model. Mol Endocrinol 24 (5):1077-89. 
Ronnemaa, E., B. Zethelius, J. Sundelof, J. Sundstrom, M. Degerman-Gunnarsson, C. Berne, L. 
Lannfelt, and L. Kilander. (2008). Impaired insulin secretion increases the risk of 
Alzheimer disease. Neurology 71 (14):1065-71. 
Roseboom, T. J., J. H. van der Meulen, C. Osmond, D. J. Barker, A. C. Ravelli, and O. P. Bleker. 
(2000). Plasma lipid profiles in adults after prenatal exposure to the Dutch famine. Am 
J Clin Nutr 72 (5):1101-6. 
Roseboom, T. J., J. H. van der Meulen, C. Osmond, D. J. Barker, A. C. Ravelli, J. M. Schroeder-
Tanka, G. A. van Montfrans, R. P. Michels, and O. P. Bleker. (2000). Coronary heart 
disease after prenatal exposure to the Dutch famine, 1944-45. Heart 84 (6):595-8. 
Ross, C. A., and M. A. Poirier. (2005). Opinion: What is the role of protein aggregation in 
neurodegeneration? Nat Rev Mol Cell Biol 6 (11):891-8. 
Rotwein, P., S. K. Burgess, J. D. Milbrandt, and J. E. Krause. (1988). Differential expression of 
insulin-like growth factor genes in rat central nervous system. Proc Natl Acad Sci U S 
A 85 (1):265-9. 
Rovelet-Lecrux, A., D. Hannequin, G. Raux, N. Le Meur, A. Laquerriere, A. Vital, C. 
Dumanchin, S. Feuillette, A. Brice, M. Vercelletto, F. Dubas, T. Frebourg, and D. 
Campion. (2006). APP locus duplication causes autosomal dominant early-onset 
Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38 (1):24-6. 
Rubin, J. B., M. A. Shia, and P. F. Pilch. (1983). Stimulation of tyrosine-specific phosphorylation 
in vitro by insulin-like growth factor I. Nature 305 (5933):438-40. 
www.intechopen.com
Role of Central Insulin-Like Growth Factor-1  
Receptor Signalling in Ageing and Endocrine Regulation 
 
253 
Rubin, R., and R. Baserga. (1995). Insulin-like growth factor-I receptor. Its role in cell 
proliferation, apoptosis, and tumorigenicity. Lab Invest 73 (3):311-31. 
Rudman, D., A. G. Feller, H. S. Nagraj, G. A. Gergans, P. Y. Lalitha, A. F. Goldberg, R. A. 
Schlenker, L. Cohn, I. W. Rudman, and D. E. Mattson. (1990). Effects of human 
growth hormone in men over 60 years old. N Engl J Med 323 (1):1-6. 
Rudman, D., M. H. Kutner, C. M. Rogers, M. F. Lubin, G. A. Fleming, and R. P. Bain. (1981). 
Impaired growth hormone secretion in the adult population: relation to age and 
adiposity. J Clin Invest 67 (5):1361-9. 
Russo, V. C., P. D. Gluckman, E. L. Feldman, and G. A. Werther. (2005). The insulin-like 
growth factor system and its pleiotropic functions in brain. Endocr Rev 26 (7):916-43. 
Russo, V. C., B. S. Schutt, E. Andaloro, S. I. Ymer, A. Hoeflich, M. B. Ranke, L. A. Bach, and G. 
A. Werther. (2005). Insulin-like growth factor binding protein-2 binding to 
extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, 
and invasion. Endocrinology 146 (10):4445-55. 
Sakano, K., T. Enjoh, F. Numata, H. Fujiwara, Y. Marumoto, N. Higashihashi, Y. Sato, J. F. 
Perdue, and Y. Fujita-Yamaguchi. (1991). The design, expression, and characterization 
of human insulin-like growth factor II (IGF-II) mutants specific for either the IGF-
II/cation-independent mannose 6-phosphate receptor or IGF-I receptor. J Biol Chem 
266 (31):20626-35. 
Saltiel, A. R., and C. R. Kahn. (2001). Insulin signalling and the regulation of glucose and lipid 
metabolism. Nature 414 (6865):799-806. 
Sauer, B. (1998). Inducible gene targeting in mice using the Cre/lox system. Methods 14 (4):381-
92. 
Sawka-Verhelle, D., V. Baron, I. Mothe, C. Filloux, M. F. White, and E. Van Obberghen. (1997). 
Tyr624 and Tyr628 in insulin receptor substrate-2 mediate its association with the 
insulin receptor. J Biol Chem 272 (26):16414-20. 
Sawka-Verhelle, D., S. Tartare-Deckert, M. F. White, and E. Van Obberghen. (1996). Insulin 
receptor substrate-2 binds to the insulin receptor through its phosphotyrosine-
binding domain and through a newly identified domain comprising amino acids 591-
786. J Biol Chem 271 (11):5980-3. 
Schedlich, L. J., T. F. Young, S. M. Firth, and R. C. Baxter. (1998). Insulin-like growth factor-
binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway 
in T47D human breast carcinoma cells. J Biol Chem 273 (29):18347-52. 
Schellenberg, G. D., T. D. Bird, E. M. Wijsman, H. T. Orr, L. Anderson, E. Nemens, J. A. White, 
L. Bonnycastle, J. L. Weber, M. E. Alonso, and et al. (1992). Genetic linkage evidence 
for a familial Alzheimer's disease locus on chromosome 14. Science 258 (5082):668-71. 
Schubert, M., D. P. Brazil, D. J. Burks, J. A. Kushner, J. Ye, C. L. Flint, J. Farhang-Fallah, P. 
Dikkes, X. M. Warot, C. Rio, G. Corfas, and M. F. White. (2003). Insulin receptor 
substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J 
Neurosci 23 (18):7084-92. 
Schubert, M., D. Gautam, D. Surjo, K. Ueki, S. Baudler, D. Schubert, T. Kondo, J. Alber, N. 
Galldiks, E. Kustermann, S. Arndt, A. H. Jacobs, W. Krone, C. R. Kahn, and J. C. 
Bruning. (2004). Role for neuronal insulin resistance in neurodegenerative diseases. 
Proc Natl Acad Sci U S A 101 (9):3100-5. 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
254 
Schutt, B. S., M. Langkamp, U. Rauschnabel, M. B. Ranke, and M. W. Elmlinger. (2004). 
Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor 
cells. J Mol Endocrinol 32 (3):859-68. 
Seino, S., and G. I. Bell. (1989). Alternative splicing of human insulin receptor messenger RNA. 
Biochem Biophys Res Commun 159 (1):312-6. 
Seino, S., M. Seino, S. Nishi, and G. I. Bell. (1989). Structure of the human insulin receptor gene 
and characterization of its promoter. Proc Natl Acad Sci U S A 86 (1):114-8. 
Selkoe, D. J. (2004). Cell biology of protein misfolding: the examples of Alzheimer's and 
Parkinson's diseases. Nat Cell Biol 6 (11):1054-61. 
Selman, C., S. Lingard, A. I. Choudhury, R. L. Batterham, M. Claret, M. Clements, F. 
Ramadani, K. Okkenhaug, E. Schuster, E. Blanc, M. D. Piper, H. Al-Qassab, J. R. 
Speakman, D. Carmignac, I. C. Robinson, J. M. Thornton, D. Gems, L. Partridge, and 
D. J. Withers. (2008). Evidence for lifespan extension and delayed age-related 
biomarkers in insulin receptor substrate 1 null mice. FASEB J 22 (3):807-18. 
Sharfi, H., and H. Eldar-Finkelman. (2008). Sequential phosphorylation of insulin receptor 
substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role 
in hepatic insulin signaling. Am J Physiol Endocrinol Metab 294 (2):E307-15. 
Shechter, M., S. Ginsberg, M. Scheinowitz, M. S. Feinberg, and Z. Laron. (2007). Obese adults 
with primary growth hormone resistance (Laron Syndrome) have normal endothelial 
function. Growth Horm IGF Res 17 (2):165-70. 
Sherrington, R., S. Froelich, S. Sorbi, D. Campion, H. Chi, E. A. Rogaeva, G. Levesque, E. I. 
Rogaev, C. Lin, Y. Liang, M. Ikeda, L. Mar, A. Brice, Y. Agid, M. E. Percy, F. Clerget-
Darpoux, S. Piacentini, G. Marcon, B. Nacmias, L. Amaducci, T. Frebourg, L. Lannfelt, 
J. M. Rommens, and P. H. St George-Hyslop. (1996). Alzheimer's disease associated 
with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 5 
(7):985-8. 
Siddle, K., M. A. Soos, C. E. Field, and B. T. Nave. (1994). Hybrid and atypical insulin/insulin-
like growth factor I receptors. Horm Res 41 Suppl 2:56-64; discussion 65. 
Sjogren, K., J. L. Liu, K. Blad, S. Skrtic, O. Vidal, V. Wallenius, D. LeRoith, J. Tornell, O. G. 
Isaksson, J. O. Jansson, and C. Ohlsson. (1999). Liver-derived insulin-like growth 
factor I (IGF-I) is the principal source of IGF-I in blood but is not required for 
postnatal body growth in mice. Proc Natl Acad Sci U S A 96 (12):7088-92. 
Skovronsky, D. M., D. B. Moore, M. E. Milla, R. W. Doms, and V. M. Lee. (2000). Protein kinase 
C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-
beta precursor protein in the trans-golgi network. J Biol Chem 275 (4):2568-75. 
Slee, E. A., D. J. O'Connor, and X. Lu. (2004). To die or not to die: how does p53 decide? 
Oncogene 23 (16):2809-18. 
Sleegers, K., N. Brouwers, I. Gijselinck, J. Theuns, D. Goossens, J. Wauters, J. Del-Favero, M. 
Cruts, C. M. van Duijn, and C. Van Broeckhoven. (2006). APP duplication is sufficient 
to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 
129 (Pt 11):2977-83. 
Solinas, G., W. Naugler, F. Galimi, M. S. Lee, and M. Karin. (2006). Saturated fatty acids inhibit 
induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-
receptor substrates. Proc Natl Acad Sci U S A 103 (44):16454-9. 
Sompol, P., W. Ittarat, J. Tangpong, Y. Chen, I. Doubinskaia, I. Batinic-Haberle, H. M. Abdul, 
D. A. Butterfield, and D. K. St Clair. (2008). A neuronal model of Alzheimer's disease: 
www.intechopen.com
Role of Central Insulin-Like Growth Factor-1  
Receptor Signalling in Ageing and Endocrine Regulation 
 
255 
an insight into the mechanisms of oxidative stress-mediated mitochondrial injury. 
Neuroscience 153 (1):120-30. 
Song, G., G. Ouyang, and S. Bao. (2005). The activation of Akt/PKB signaling pathway and cell 
survival. J Cell Mol Med 9 (1):59-71. 
Sonntag, W. E., R. W. Steger, L. J. Forman, and J. Meites. (1980). Decreased pulsatile release of 
growth hormone in old male rats. Endocrinology 107 (6):1875-9. 
Sontag, E., V. Nunbhakdi-Craig, G. Lee, G. S. Bloom, and M. C. Mumby. (1996). Regulation of 
the phosphorylation state and microtubule-binding activity of Tau by protein 
phosphatase 2A. Neuron 17 (6):1201-7. 
Soos, M. A., and K. Siddle. (1989). Immunological relationships between receptors for insulin 
and insulin-like growth factor I. Evidence for structural heterogeneity of insulin-like 
growth factor I receptors involving hybrids with insulin receptors. Biochem J 263 
(2):553-63. 
Soos, M. A., J. Whittaker, R. Lammers, A. Ullrich, and K. Siddle. (1990). Receptors for insulin 
and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid 
receptors in transfected cells. Biochem J 270 (2):383-90. 
Soto, C. (2003). Unfolding the role of protein misfolding in neurodegenerative diseases. Nat 
Rev Neurosci 4 (1):49-60. 
Sotthibundhu, A., A. M. Sykes, B. Fox, C. K. Underwood, W. Thangnipon, and E. J. Coulson. 
(2008). Beta-amyloid(1-42) induces neuronal death through the p75 neurotrophin 
receptor. J Neurosci 28 (15):3941-6. 
St George-Hyslop, P., J. Haines, E. Rogaev, M. Mortilla, G. Vaula, M. Pericak-Vance, J. F. 
Foncin, M. Montesi, A. Bruni, S. Sorbi, and et al. (1992). Genetic evidence for a novel 
familial Alzheimer's disease locus on chromosome 14. Nat Genet 2 (4):330-4. 
Stewart, C. E., and P. Rotwein. (1996). Growth, differentiation, and survival: multiple 
physiological functions for insulin-like growth factors. Physiol Rev 76 (4):1005-26. 
Stewart, R., and D. Liolitsa. (1999). Type 2 diabetes mellitus, cognitive impairment and 
dementia. Diabet Med 16 (2):93-112. 
Stokoe, D., L. R. Stephens, T. Copeland, P. R. Gaffney, C. B. Reese, G. F. Painter, A. B. Holmes, 
F. McCormick, and P. T. Hawkins. (1997). Dual role of phosphatidylinositol-3,4,5-
trisphosphate in the activation of protein kinase B. Science 277 (5325):567-70. 
Stoothoff, W. H., and G. V. Johnson. (2005). Tau phosphorylation: physiological and 
pathological consequences. Biochim Biophys Acta 1739 (2-3):280-97. 
Suh Y, Atzmon G, Cho MO, Hwang D, Liu B, Leahy DJ, Barzilai N, Cohen P.  (2008). 
Functionally significant insulin-like growth factor I receptor mutations in 
centenarians. Proc Natl Acad Sci U S A 105(9):3438-3442.  
Sun, X. J., P. Rothenberg, C. R. Kahn, J. M. Backer, E. Araki, P. A. Wilden, D. A. Cahill, B. J. 
Goldstein, and M. F. White. (1991). Structure of the insulin receptor substrate IRS-1 
defines a unique signal transduction protein. Nature 352 (6330):73-7. 
Svensson, J., M. Diez, J. Engel, C. Wass, A. Tivesten, J. O. Jansson, O. Isaksson, T. Archer, T. 
Hokfelt, and C. Ohlsson. (2006). Endocrine, liver-derived IGF-I is of importance for 
spatial learning and memory in old mice. J Endocrinol 189 (3):617-27. 
Tabaton, M., and E. Tamagno. (2007). The molecular link between beta- and gamma-secretase 
activity on the amyloid beta precursor protein. Cell Mol Life Sci 64 (17):2211-8. 
Taguchi, A., L. M. Wartschow, and M. F. White. (2007). Brain IRS2 signaling coordinates life 
span and nutrient homeostasis. Science 317 (5836):369-72. 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
256 
Taguchi, A., and M. F. White. (2008). Insulin-like signaling, nutrient homeostasis, and life span. 
Annu Rev Physiol 70:191-212. 
Tang, E. D., G. Nunez, F. G. Barr, and K. L. Guan. (1999). Negative regulation of the forkhead 
transcription factor FKHR by Akt. J Biol Chem 274 (24):16741-6. 
Tang, Z., R. Yu, Y. Lu, A. F. Parlow, and J. L. Liu. (2005). Age-dependent onset of liver-specific 
IGF-I gene deficiency and its persistence in old age: implications for postnatal growth 
and insulin resistance in LID mice. Am J Physiol Endocrinol Metab 289 (2):E288-95. 
Tannenbaum, G. S., and J. B. Martin. (1976). Evidence for an endogenous ultradian rhythm 
governing growth hormone secretion in the rat. Endocrinology 98 (3):562-70. 
Tanzi, R. E., J. F. Gusella, P. C. Watkins, G. A. Bruns, P. St George-Hyslop, M. L. Van Keuren, 
D. Patterson, S. Pagan, D. M. Kurnit, and R. L. Neve. (1987). Amyloid beta protein 
gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. 
Science 235 (4791):880-4. 
Tanzi, R. E., R. D. Moir, and S. L. Wagner. (2004). Clearance of Alzheimer's Abeta peptide: the 
many roads to perdition. Neuron 43 (5):605-8. 
Tanzi, R. E., G. Vaula, D. M. Romano, M. Mortilla, T. L. Huang, R. G. Tupler, W. Wasco, B. T. 
Hyman, J. L. Haines, B. J. Jenkins, and et al. (1992). Assessment of amyloid beta-
protein precursor gene mutations in a large set of familial and sporadic Alzheimer 
disease cases. Am J Hum Genet 51 (2):273-82. 
Tatar, M., A. Bartke, and A. Antebi. (2003). The endocrine regulation of aging by insulin-like 
signals. Science 299 (5611):1346-51. 
Tatar, M., A. Kopelman, D. Epstein, M. P. Tu, C. M. Yin, and R. S. Garofalo. (2001). A mutant 
Drosophila insulin receptor homolog that extends life-span and impairs 
neuroendocrine function. Science 292 (5514):107-10. 
Toivonen, J. M., and L. Partridge. (2009). Endocrine regulation of aging and reproduction in 
Drosophila. Mol Cell Endocrinol 299 (1):39-50. 
Trejo, J. L., E. Carro, and I. Torres-Aleman. (2001). Circulating insulin-like growth factor I 
mediates exercise-induced increases in the number of new neurons in the adult 
hippocampus. J Neurosci 21 (5):1628-34. 
Trejo, J. L., M. V. Llorens-Martin, and I. Torres-Aleman. (2008). The effects of exercise on 
spatial learning and anxiety-like behavior are mediated by an IGF-I-dependent 
mechanism related to hippocampal neurogenesis. Mol Cell Neurosci 37 (2):402-11. 
Tu, M. P., D. Epstein, and M. Tatar. (2002). The demography of slow aging in male and female 
Drosophila mutant for the insulin-receptor substrate homologue chico. Aging Cell 1 
(1):75-80. 
Ullrich, A., A. Gray, A. W. Tam, T. Yang-Feng, M. Tsubokawa, C. Collins, W. Henzel, T. Le 
Bon, S. Kathuria, E. Chen, and et al. (1986). Insulin-like growth factor I receptor 
primary structure: comparison with insulin receptor suggests structural determinants 
that define functional specificity. EMBO J 5 (10):2503-12. 
Valentino, K. L., I. Ocrant, and R. G. Rosenfeld. (1990). Developmental expression of insulin-
like growth factor-II receptor immunoreactivity in the rat central nervous system. 
Endocrinology 126 (2):914-20. 
van der Horst, A., A. M. de Vries-Smits, A. B. Brenkman, M. H. van Triest, N. van den Broek, 
F. Colland, M. M. Maurice, and B. M. Burgering. (2006). FOXO4 transcriptional 
activity is regulated by monoubiquitination and USP7/HAUSP. Nat Cell Biol 8 
(10):1064-73. 
www.intechopen.com
Role of Central Insulin-Like Growth Factor-1  
Receptor Signalling in Ageing and Endocrine Regulation 
 
257 
Van Obberghen, E., M. Ksauga, A. Le Cam, J. A. Hedo, A. Itin, and L. C. Harrison. (1981). 
Biosynthetic labeling of insulin receptor: studies of subunits in cultured human IM-9 
lymphocytes. Proc Natl Acad Sci U S A 78 (2):1052-6. 
Vanhaesebroeck, B., K. Ali, A. Bilancio, B. Geering, and L. C. Foukas. (2005). Signalling by 
PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 30 (4):194-204. 
Vardy, E. R., P. J. Rice, P. C. Bowie, J. D. Holmes, P. J. Grant, and N. M. Hooper. (2007). 
Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. J 
Alzheimers Dis 12 (4):285-90. 
Vassar, R. (2004). BACE1: the beta-secretase enzyme in Alzheimer's disease. J Mol Neurosci 23 
(1-2):105-14. 
Vassar, R., B. D. Bennett, S. Babu-Khan, S. Kahn, E. A. Mendiaz, P. Denis, D. B. Teplow, S. 
Ross, P. Amarante, R. Loeloff, Y. Luo, S. Fisher, J. Fuller, S. Edenson, J. Lile, M. A. 
Jarosinski, A. L. Biere, E. Curran, T. Burgess, J. C. Louis, F. Collins, J. Treanor, G. 
Rogers, and M. Citron. (1999). Beta-secretase cleavage of Alzheimer's amyloid 
precursor protein by the transmembrane aspartic protease BACE. Science 286 
(5440):735-41. 
Veldhuis, J. D., M. Bidlingmaier, S. M. Anderson, Z. Wu, and C. J. Strasburger. (2001). 
Lowering total plasma insulin-like growth factor I concentrations by way of a 
novel, potent, and selective growth hormone (GH) receptor antagonist, 
pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and 
elevates basal/nonpulsatile GH release in healthy women and men. J Clin 
Endocrinol Metab 86 (7):3304-10. 
Veldhuis, J. D., D. M. Keenan, J. N. Bailey, A. Adeniji, J. M. Miles, R. Paulo, M. Cosma, and C. 
Soares-Welch. (2008). Estradiol supplementation in postmenopausal women 
attenuates suppression of pulsatile growth hormone secretion by recombinant human 
insulin-like growth factor type I. J Clin Endocrinol Metab 93 (11):4471-8. 
Veldhuis, J. D., D. M. Keenan, J. N. Bailey, A. Adeniji, J. M. Miles, R. Paulo, M. Cosma, and C. 
Soares-Welch. (2009). Testosterone supplementation in older men restrains insulin-
like growth factor's dose-dependent feedback inhibition of pulsatile growth hormone 
secretion. J Clin Endocrinol Metab 94 (1):246-54. 
Vicario-Abejon, C., M. J. Yusta-Boyo, C. Fernandez-Moreno, and F. de Pablo. (2003). Locally 
born olfactory bulb stem cells proliferate in response to insulin-related factors and 
require endogenous insulin-like growth factor-I for differentiation into neurons and 
glia. J Neurosci 23 (3):895-906. 
von Figura, K., and A. Hasilik. (1986). Lysosomal enzymes and their receptors. Annu Rev 
Biochem 55:167-93. 
Walsh, D. M., A. Lomakin, G. B. Benedek, M. M. Condron, and D. B. Teplow. (1997). Amyloid 
beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 272 
(35):22364-72. 
Walsh, D. M., and D. J. Selkoe. (2007). A beta oligomers - a decade of discovery. J Neurochem 
101 (5):1172-84. 
Wang, M. C., D. Bohmann, and H. Jasper. (2005). JNK extends life span and limits growth by 
antagonizing cellular and organism-wide responses to insulin signaling. Cell 121 
(1):115-25. 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
258 
Wang, S., N. Tulina, D. L. Carlin, and E. J. Rulifson. (2007). The origin of islet-like cells in 
Drosophila identifies parallels to the vertebrate endocrine axis. Proc Natl Acad Sci U S 
A 104 (50):19873-8. 
Wang, Z., K. A. Al-Regaiey, M. M. Masternak, and A. Bartke. (2006). Adipocytokines and lipid 
levels in Ames dwarf and calorie-restricted mice. J Gerontol A Biol Sci Med Sci 61 
(4):323-31. 
Weigert, C., A. M. Hennige, T. Brischmann, A. Beck, K. Moeschel, M. Schauble, K. Brodbeck, 
H. U. Haring, E. D. Schleicher, and R. Lehmann. (2005). The phosphorylation of 
Ser318 of insulin receptor substrate 1 is not per se inhibitory in skeletal muscle cells 
but is necessary to trigger the attenuation of the insulin-stimulated signal. J Biol Chem 
280 (45):37393-9. 
Werther, G. A., M. Abate, A. Hogg, H. Cheesman, B. Oldfield, D. Hards, P. Hudson, B. Power, 
K. Freed, and A. C. Herington. (1990). Localization of insulin-like growth factor-I 
mRNA in rat brain by in situ hybridization--relationship to IGF-I receptors. Mol 
Endocrinol 4 (5):773-8. 
Werther, G. A., A. Hogg, B. J. Oldfield, M. J. McKinley, R. Figdor, and F. A. Mendelsohn. 
(1989). Localization and Characterization of Insulin-Like Growth Factor-I Receptors 
in Rat Brain and Pituitary Gland Using in vitro Autoradiography and Computerized 
Densitometry* A Distinct Distribution from Insulin Receptors. J Neuroendocrinol 1 
(5):369-77. 
Werther, G. A., V. Russo, N. Baker, and G. Butler. (1998). The role of the insulin-like growth 
factor system in the developing brain. Horm Res 49 Suppl 1:37-40. 
White, M. F., and C. R. Kahn. (1994). The insulin signaling system. J Biol Chem 269 (1):1-4. 
Wilczak, N., P. De Bleser, P. Luiten, A. Geerts, A. Teelken, and J. De Keyser. (2000). Insulin-like 
growth factor II receptors in human brain and their absence in astrogliotic plaques in 
multiple sclerosis. Brain Res 863 (1-2):282-8. 
Willcox, B. J., T. A. Donlon, Q. He, R. Chen, J. S. Grove, K. Yano, K. H. Masaki, D. C. Willcox, B. 
Rodriguez, and J. D. Curb. (2008). FOXO3A genotype is strongly associated with 
human longevity. Proc Natl Acad Sci U S A 105 (37):13987-92. 
Williams, A. D., M. Sega, M. Chen, I. Kheterpal, M. Geva, V. Berthelier, D. T. Kaleta, K. D. 
Cook, and R. Wetzel. (2005). Structural properties of Abeta protofibrils stabilized by a 
small molecule. Proc Natl Acad Sci U S A 102 (20):7115-20. 
Wilmoth, J. R. (2000). Demography of longevity: past, present, and future trends. Exp Gerontol 
35 (9-10):1111-29. 
Wittmann, T., G. M. Bokoch, and C. M. Waterman-Storer. (2004). Regulation of microtubule 
destabilizing activity of Op18/stathmin downstream of Rac1. J Biol Chem 279 (7):6196-
203. 
Wolkow, C. A., K. D. Kimura, M. S. Lee, and G. Ruvkun. (2000). Regulation of C. elegans life-
span by insulinlike signaling in the nervous system. Science 290 (5489):147-50. 
Wortley, K. E., J. P. del Rincon, J. D. Murray, K. Garcia, K. Iida, M. O. Thorner, and M. W. 
Sleeman. (2005). Absence of ghrelin protects against early-onset obesity. J Clin Invest 
115 (12):3573-8. 
Yakar, S., J. L. Liu, B. Stannard, A. Butler, D. Accili, B. Sauer, and D. LeRoith. (1999). Normal 
growth and development in the absence of hepatic insulin-like growth factor I. Proc 
Natl Acad Sci U S A 96 (13):7324-9. 
www.intechopen.com
Role of Central Insulin-Like Growth Factor-1  
Receptor Signalling in Ageing and Endocrine Regulation 
 
259 
Yakar, S., J. Setser, H. Zhao, B. Stannard, M. Haluzik, V. Glatt, M. L. Bouxsein, J. J. Kopchick, 
and D. LeRoith. (2004). Inhibition of growth hormone action improves insulin 
sensitivity in liver IGF-1-deficient mice. J Clin Invest 113 (1):96-105. 
Yamaguchi, Y., J. S. Flier, A. Yokota, H. Benecke, J. M. Backer, and D. E. Moller. (1991). 
Functional properties of two naturally occurring isoforms of the human insulin 
receptor in Chinese hamster ovary cells. Endocrinology 129 (4):2058-66. 
Yamanaka, Y., J. L. Fowlkes, E. M. Wilson, R. G. Rosenfeld, and Y. Oh. (1999). Characterization 
of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast 
cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding 
domain on the IGFBP-3 molecule. Endocrinology 140 (3):1319-28. 
Yang, E., J. Zha, J. Jockel, L. H. Boise, C. B. Thompson, and S. J. Korsmeyer. (1995). Bad, a 
heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. 
Cell 80 (2):285-91. 
Yang, X. F., W. G. Beamer, H. Huynh, and M. Pollak. (1996). Reduced growth of human breast 
cancer xenografts in hosts homozygous for the lit mutation. Cancer Res 56 (7): 
1509-11. 
Yang, Z., W. Zhao, X. Zhang, R. Mu, Y. Zhai, L. Kong, and C. Chen. (2008). Impact of famine 
during pregnancy and infancy on health in adulthood. Obes Rev 9 Suppl 1:95-9. 
Ye, P., J. Carson, and A. J. D'Ercole. (1995). In vivo actions of insulin-like growth factor-I (IGF-I) 
on brain myelination: studies of IGF-I and IGF binding protein-1 (IGFBP-1) transgenic 
mice. J Neurosci 15 (11):7344-56. 
Ye, P., L. Li, R. G. Richards, R. P. DiAugustine, and A. J. D'Ercole. (2002). Myelination is altered 
in insulin-like growth factor-I null mutant mice. J Neurosci 22 (14):6041-51. 
Yenush, L., and M.F.White MF. (1997). The IRS-signalling system during insulin and cytokine 
action. Bioessays 19(6):491-500 
Yin, P., Q. Xu, and C. Duan. (2004). Paradoxical actions of endogenous and exogenous insulin-
like growth factor-binding protein-5 revealed by RNA interference analysis. J Biol 
Chem 279 (31):32660-6. 
Yuan, R., S. W. Tsaih, S. B. Petkova, C. Marin de Evsikova, S. Xing, M. A. Marion, M. A. 
Bogue, K. D. Mills, L. L. Peters, C. J. Bult, C. J. Rosen, J. P. Sundberg, D. E. 
Harrison, G. A. Churchill, and B. Paigen. (2009). Aging in inbred strains of mice: 
study design and interim report on median lifespans and circulating IGF1 levels. 
Aging Cell 8 (3):277-87. 
Zha, J., H. Harada, K. Osipov, J. Jockel, G. Waksman, and S. J. Korsmeyer. (1997). BH3 domain 
of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J 
Biol Chem 272 (39):24101-4. 
Zhang, C. L., Y. Zou, W. He, F. H. Gage, and R. M. Evans. (2008). A role for adult TLX-positive 
neural stem cells in learning and behaviour. Nature 451 (7181):1004-7. 
Zhang, S., K. Iwata, M. J. Lachenmann, J. W. Peng, S. Li, E. R. Stimson, Y. Lu, A. M. Felix, J. E. 
Maggio, and J. P. Lee. (2000). The Alzheimer's peptide a beta adopts a collapsed coil 
structure in water. J Struct Biol 130 (2-3):130-41. 
Zhao, L., B. Teter, T. Morihara, G. P. Lim, S. S. Ambegaokar, O. J. Ubeda, S. A. Frautschy, and 
G. M. Cole. (2004). Insulin-degrading enzyme as a downstream target of insulin 
receptor signaling cascade: implications for Alzheimer's disease intervention. J 
Neurosci 24 (49):11120-6. 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
260 
Zigman, J. M., Y. Nakano, R. Coppari, N. Balthasar, J. N. Marcus, C. E. Lee, J. E. Jones, A. E. 
Deysher, A. R. Waxman, R. D. White, T. D. Williams, J. L. Lachey, R. J. Seeley, B. B. 
Lowell, and J. K. Elmquist. (2005). Mice lacking ghrelin receptors resist the 
development of diet-induced obesity. J Clin Invest 115 (12):3564-72. 
www.intechopen.com
Basic and Clinical Endocrinology Up-to-Date
Edited by Dr. Fulya Akin
ISBN 978-953-307-340-8
Hard cover, 350 pages
Publisher InTech
Published online 17, October, 2011
Published in print edition October, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book provides the most up-to-date information on the basic and clinical aspects of endocrinology. It offers
both researchers and clinicians experts, gold-standard analysis of endocrine research and translation into the
treatment of diseases such as insulinoma, endocrine disease in pregnancy and steroid induced osteoporosis.
Investigates both the endocrine functions of the kidneys and how the kidney acts as a target for hormones
from other organ systems. Presents a uniquely comprehensive look at all aspects of endocrine changes in
pregnancy and cardiovascular effects of androgens.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Lorna Moll, Johanna Zemva and Markus Schubert (2011). Role of Central Insulin-Like Growth Factor-1
Receptor Signalling in Ageing and Endocrine Regulation, Basic and Clinical Endocrinology Up-to-Date, Dr.
Fulya Akin (Ed.), ISBN: 978-953-307-340-8, InTech, Available from: http://www.intechopen.com/books/basic-
and-clinical-endocrinology-up-to-date/role-of-central-insulin-like-growth-factor-1-receptor-signalling-in-ageing-
and-endocrine-regulation
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
